Anti-integrin antibodies and uses thereof

Antibodies specifically binding to αvβ1 integrin with high affinity address the challenge of cross-reactivity, effectively inhibiting TGFβ signaling for targeted treatment of fibrotic diseases and cancer.

JP2024159818AInactive Publication Date: 2024-11-08BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024137633
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-08
Filing Date
2024-08-19
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current technologies face challenges in developing anti-integrin antibodies that specifically target αvβ1 integrin without binding to other integrins, which are crucial for treating diseases such as fibrosis and cancer, due to the difficulty in generating heterodimer-specific antibodies given the widespread expression of α and β subunits in various integrin pairs.

Method used

Development of antibodies that specifically bind to αvβ1 integrin with high affinity (KD ≦20 nM) and do not interact with other integrins, including cation-dependent and cation-independent variants, which can inhibit fibroblast TGFβ responses and are suitable for treating fibrotic diseases and cancer.

Benefits of technology

The antibodies effectively inhibit αvβ1 integrin activity, reducing downstream effects of TGFβ signaling and providing therapeutic benefits for fibrotic diseases and cancer by specifically targeting αvβ1 integrin without cross-reactivity, thus offering a targeted treatment approach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159818000034
    Figure 2024159818000034
  • Figure 2024159818000035
    Figure 2024159818000035
  • Figure 2024159818000036
    Figure 2024159818000036
Patent Text Reader

Abstract

To provide anti-integrin antibodies and uses thereof.SOLUTION: Anti-integrin antibodies are disclosed. Also disclosed are methods of using the antibodies to treat or prevent disorders such as fibrotic diseases, cancer, ophthalmology disorders, and NAFLD. Further disclosed are methods of selecting an antibody that specifically binds to αvβ1, or that binds to αvβ1 and αvβ6, or that binds to one or more members of the RGD sub-family of integrins. In one aspect, this disclosure features an antibody that specifically binds to αvβ1 integrin but not to other integrins.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 830,961, filed April 8, 2019, the contents of which are incorporated herein by reference in their entirety.

[0002] The present invention relates generally to anti-integrin antibodies (eg, antibodies that bind to one or more members of the RGD subfamily of integrins) and uses thereof. [Background technology]

[0003] Integrins are cell adhesion receptors that play important roles in developmental and pathological processes. Integrins are widely expressed and all nucleated cells in the body have a specific integrin signature. These receptors are composed of non-covalently associated alpha (α) and beta (β) chains that combine to obtain a variety of heterodimeric proteins with different cell and adhesion specificities. The integrin family is composed of 24 αβ heterodimeric members that mediate the attachment of cells to the extracellular matrix (ECM) but are also involved in specialized cell-cell interactions. The α and β subunits do not show homology to each other, but different α subunits have similarities between them and there are conserved regions in different integrin β subunits. A subset of integrins (8 of 24) recognizes RGD sequences (arginine (R), glycine (G), and aspartic acid (D)) in natural ligands and are also called RGD-binding integrins, including αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3 integrins. Integrins are involved in regulating various cellular processes, including cell adhesion, migration, invasion, differentiation, proliferation, apoptosis, and gene expression. Thus, there is a need to develop anti-integrin antibodies useful for treating diseases involving the integrin pathway, such as fibrotic diseases, ophthalmic diseases, and cancer. Summary of the Invention [Means for solving the problem]

[0004] In one aspect, the disclosure features an antibody that specifically binds to αvβ1 integrin but not to other integrins. In some embodiments, the antibody does not bind to other αv or β1-containing integrin heterodimers. In some embodiments, the anti-αvβ1 antibody does not bind to other RGD integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3 integrin). In some embodiments, the antibody competes with and / or binds to the same epitope as a reference anti-αvβ1 integrin antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the VH and VL of the reference antibody being: (i) the amino acid sequence set forth in SEQ ID NO: 11 and the amino acid sequence set forth in SEQ ID NO: 12, respectively; (ii) the amino acid sequence set forth in SEQ ID NO: 21 and the amino acid sequence set forth in SEQ ID NO: 22, respectively; (iii) the amino acid sequence set forth in SEQ ID NO: 27 and the amino acid sequence set forth in SEQ ID NO: 28, respectively; (iv) the amino acid sequence set forth in SEQ ID NO: 30 and the amino acid sequence set forth in SEQ ID NO: 12, respectively; (v) (vi) the amino acid sequence shown in SEQ ID NO: 44 and the amino acid sequence shown in SEQ ID NO: 45, respectively; (vii) the amino acid sequence shown in SEQ ID NO: 49 and the amino acid sequence shown in SEQ ID NO: 50, respectively; (viii) the amino acid sequence shown in SEQ ID NO: 57 and the amino acid sequence shown in SEQ ID NO: 58, respectively; (ix) the amino acid sequence shown in SEQ ID NO: 61 and the amino acid sequence shown in SEQ ID NO: 58, respectively; or (x) the amino acid sequence shown in SEQ ID NO: 64 and the amino acid sequence shown in SEQ ID NO: 58, respectively.

[0005] In another aspect, the disclosure features an antibody that specifically binds to both αvβ1 and αvβ6 integrins but not to other integrins. In some embodiments, the antibody does not bind to other αv, β1, or β6-containing integrin heterodimers. In some cases, the antibody does not bind to RGD-binding integrins other than αvβ1 and αvβ6 integrins (e.g., αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3). In some embodiments, the antibody binds to both αvβ1 and αvβ6 integrins and competes with and / or binds to the same epitope as a reference antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL of the reference antibody comprise (i) the amino acid sequence set forth in SEQ ID NO: 44 and the amino acid sequence set forth in SEQ ID NO: 68, respectively; (ii) the amino acid sequence set forth in SEQ ID NO: 44 and the amino acid sequence set forth in SEQ ID NO: 70, respectively; (iii) the amino acid sequence set forth in SEQ ID NO: 49 and the amino acid sequence set forth in SEQ ID NO: 72, respectively; or (iv) the amino acid sequence set forth in SEQ ID NO: 76 and the amino acid sequence set forth in SEQ ID NO: 77, respectively.

[0006] In another aspect, the disclosure features an antibody that specifically binds to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3. In some embodiments, the antibody binds to αvβ1 and αvβ8. In some embodiments, the antibody binds to αvβ1 and αvβ3. In some embodiments, the antibody binds to αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8. In some embodiments, the antibody does not bind to an integrin other than one or more of the RGD-binding integrins. In some embodiments, the antibody competes with and / or binds to the same epitope as a reference antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL of the reference antibody comprise (i) the amino acid sequence set forth in SEQ ID NO: 82 and the amino acid sequence set forth in SEQ ID NO: 83, respectively; (ii) the amino acid sequence set forth in SEQ ID NO: 92 and the amino acid sequence set forth in SEQ ID NO: 93, respectively; (iii) the amino acid sequence set forth in SEQ ID NO: 92 and the amino acid sequence set forth in SEQ ID NO: 95, respectively; (iv) the amino acid sequence set forth in SEQ ID NO: 100 and the amino acid sequence set forth in SEQ ID NO: 28, respectively; (v) the amino acid sequence set forth in SEQ ID NO: 21 and the amino acid sequence set forth in SEQ ID NO: 104, respectively; or (vi) the amino acid sequence set forth in SEQ ID NO: 49 and the amino acid sequence set forth in SEQ ID NO: 107, respectively.

[0007] In another aspect, the disclosure features an antibody that specifically binds to human αvβ1 and has one or more (e.g., one, two, three, four, or five) of the following properties: (i) binds with high affinity (bivalent affinity) to human αvβ1 with a KD≦20 nM; (ii) blocks αvβ1 interaction with its ligands (e.g., LAP and fibronectin); (iii) is cation-dependent (e.g., calcium and magnesium, or manganese) or cation-independent for binding to human αvβ1; (iv) binds αvβ1 on fibroblasts; and (v) inhibits fibroblast TGFβ responses (e.g., as assessed by an LPA-induced PAI-1 assay). In some embodiments, the antibody is internalized. In some embodiments, the antibody binds to cynomolgus monkey, mouse, and rat αvβ1. In some embodiments, the antibody comprises the VH CDR1, VH CDR2, and VH CDR3 of exemplary antibodies 1-10. In some embodiments, the antibody comprises the VL CDR1, VL CDR2, and VL CDR3 of Exemplary Antibodies 1-10. In some embodiments, the antibody competes with and / or binds to the same epitope as a reference anti-αvβ1 integrin antibody that comprises the VH and VL of Exemplary Antibodies 1-10.

[0008] In another aspect, the disclosure features an antibody that specifically binds to both human αvβ1 and human αvβ6 and has one or more (e.g., one, two, three, four, or five) of the following properties: (i) binds to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to human αvβ6 with affinity (bivalent affinity) of 100 nM, (ii) blocks αvβ1 and / or αvβ6 interaction with its ligands (e.g., LAP and fibronectin), (iii) is cation-dependent (e.g., calcium and magnesium, or manganese) for binding to human αvβ1 and / or αvβ6, (iv) binds to αvβ1 on fibroblasts, and (v) inhibits fibroblast TGFβ responses (e.g., as assessed by an LPA-induced PAI-1 assay). In some embodiments, the antibody comprises the VH CDR1, VH CDR2, and VH CDR3 of exemplary antibodies 11-14. In some embodiments, the antibody comprises the VL CDR1, VL CDR2, and VL CDR3 of exemplary antibodies 11-14. In some embodiments, the antibody competes with and / or binds to the same epitope as a reference antibody that binds to both αvβ1 and αvβ6 integrins and comprises the VH and VL of exemplary antibodies 11-14.

[0009] In another aspect, the disclosure features an antibody that specifically binds to both human αvβ1 and one or more of other RGD-binding integrins and has one or more (e.g., one, two, three, four, or five) of the following properties: (i) binds to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to other RGD-binding integrins with affinity (bivalent affinity) of 100 nM, (ii) blocks αvβ1 and / or RGD family integrin interactions with its ligands (e.g., LAP and fibronectin), (iii) is cation-dependent (e.g., calcium and magnesium, or manganese) or cation-independent for binding to human αvβ1 and / or RGD-binding integrins, (iv) binds to αvβ1 and / or RGD-binding integrins on fibroblasts, and (v) inhibits fibroblast TGFβ responses (e.g., as assessed by an LPA-induced PAI-1 assay). In some embodiments, the antibody is internalized. In some embodiments, the antibody binds to cynomolgus monkey, mouse, and rat αvβ1. In some embodiments, the antibody binds to the VH of Exemplary Antibodies 15-20. Includes CDR1, VH CDR2, and VH CDR3.

[0010] In some embodiments, the antibody comprises the VL CDR1, VL CDR2, and VL CDR3 of Exemplary Antibodies 15-20. In some embodiments, the antibody competes with and / or binds to the same epitope as a reference antibody comprising the VH and VL of Exemplary Antibodies 15-20.

[0011] In another aspect, the present disclosure provides a method for the treatment of cancer, comprising administering to a patient a cancer cell that specifically binds to both human αvβ1 and / or one or more of other RGD-binding integrins, (i) binds to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and (if it also binds to other RGD family integrins) binds to other RGD-binding integrins with affinity (bivalent affinity) of 100 nM, (ii) blocks αvβ1 and / or RGD family integrin interactions with their ligands (e.g., LAP and fibronectin), (iii) inhibits the expression of human αvβ1 and / or RGD-binding integrins, and (iv) inhibits the expression of human αvβ1 and / or RGD-binding integrins. The antibodies are characterized by one or more (e.g., one, two, three, four, five, six, or seven) of the following properties: (i) are cation-dependent (e.g., calcium and magnesium, or manganese) or cation-independent for binding to integrins; (iv) bind to αvβ1 and / or RGD-binding integrins on fibroblasts; (v) inhibit fibroblast TGFβ responses (e.g., as assessed by an LPA-induced PAI-1 assay); (vi) are internalized; and (vii) bind to cynomolgus monkey, mouse, and rat αvβ1.

[0012] In another aspect, the disclosure features an antibody that binds to αvβ1 integrin but not to other integrins (e.g., other RGD family integrins). The antibody comprises a VH comprising VHCDR1, VHCDR2, and VHCDR3, and a VL comprising VLCDR1, VLCDR2, and VLCDR3, where VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 are (i) SEQ ID NOs: 4, 6, 7, 8, 9, and 10, respectively, (ii) SEQ ID NOs: 14, 16, 17, 18, 19, and 20, respectively, (iii) SEQ ID NOs: 4, 6, 23, 24, 25, and 26, respectively, (iv) SEQ ID NO: 29, (v) SEQ ID NOs: 32, 34, 17, 18, 19, and 20, respectively; (vi) SEQ ID NOs: 37, 39, 40, 41, 42, and 43, respectively; (vii) SEQ ID NOs: 37, 39, 46, 18, 47, and 48, respectively; (viii) SEQ ID NOs: 52, 54, 55, 18, 19, and 56, respectively; (ix) SEQ ID NOs: 60, 39, 55, 18, 19, and 56, respectively; or (x) SEQ ID NOs: 63, 54, 55, 18, 19, and 56, respectively.

[0013] In some embodiments of the above aspects, the anti-αvβ1 antibody has (i) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:11, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:12; (ii) a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:21; 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:22, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:23, (iii) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:27, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:28, (iv) a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:30, and a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:12. (v) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 22; (vi) a VL that is at least 75%, 80%, 85%, 90%,(vii) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 45; and (vii) a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 49; or 100% identical to the amino acid sequence set forth in SEQ ID NO:50, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:50; (viii) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:57, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:58. (ix) a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 61; and a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 58. 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 64; (x) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 64; and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 58.

[0014] In some embodiments of the above aspects, the anti-αvβ1 antibody comprises: (i) a VH that contains 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO:11; and a VL that contains 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO:12; (iii) a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 22, and a VL containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 27; (iv) a VH comprising up to 20 (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO:28; (v) a VH comprising up to 20 (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO:30; (v) a VL containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 35; and (vi) a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 22.(vi) a VH comprising 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 44, and a VL comprising 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 45; (vii) a VH comprising 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 49. (viii) a VH having 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 50; and a VL having 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 57; (ix) a VH having 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 58; (ix) a VH having 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 61; (x) a VL having 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 58; (x) a VH having 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 64; and12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions.

[0015] In another aspect, the disclosure features an antibody that binds to both αvβ1 and αvβ6 integrin but does not bind to other integrins (e.g., other RGD family integrins), comprising a VH comprising VHCDR1, VHCDR2 and VHCDR3, and a VL comprising VLCDR1, VLCDR2, and VLCDR3, wherein VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 comprise (i) SEQ ID NOs: 37, 39, 40, 65, 66, and 67, respectively; (ii) SEQ ID NOs: 37, 39, 40, 65, 66, and 69, respectively; (iii) SEQ ID NOs: 37, 39, 46, 18, 47, and 71, respectively; or (iv) SEQ ID NOs: 37, 39, 73, 74, 42, and 75, respectively.

[0016] In some embodiments of the above aspects, the antibody that binds to both αvβ1 and αvβ6 integrins but not other integrins comprises (i) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:44, and a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:68. %, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:44; (ii) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:70; %, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:49; (iii) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:72; or 100% identical to the amino acid sequence set forth in SEQ ID NO:77; (iv) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:76; and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:77.

[0017] In some embodiments of the above aspects, the antibody that binds to both αvβ1 and αvβ6 integrins but not other integrins comprises: (i) a VH that contains 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO:44; and (ii) a VH that contains 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12 ... (ii) a VL containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 44, and a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 70. (iii) a VH containing 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO:49, and 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO:72. , insertions or deletions; (iv) a VH containing 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 76; and a VL containing 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 77.

[0018] In another aspect, the disclosure provides an antibody that binds to αvβ1 and one or more integrins selected from the group consisting of αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3, comprising a VH comprising VHCDR1, VHCDR2, and VHCDR3, and a VL comprising VLCDR1, VLCDR2, and VLCDR3, wherein VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 are (i) respectively: (ii) SEQ ID NOs: 85, 87, 88, 89, 90, and 91, respectively; (iii) SEQ ID NOs: 85, 87, 88, 89, 90, and 94, respectively; (iv) SEQ ID NOs: 97, 99, 23, 24, 25, and 26, respectively; (v) SEQ ID NOs: 14, 16, 17, 101, 102, and 103, respectively; or (vi) SEQ ID NOs: 37, 39, 46, 105, 80, and 106, respectively.

[0019] In some embodiments of the above aspect, the antibody that binds to αvβ1 and one or more integrins selected from the group consisting of αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3 has (i) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 82, and a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 83. 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:92; (ii) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:92, and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:93; (iii) a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:92. 95、(iv) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 100, and and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:28; (v) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:21; and a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:104;97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 49; and (vi) a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 49; and a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 107.

[0020] In some embodiments of the above aspects, the antibody that binds to αvβ1 and one or more integrins selected from the group consisting of αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3 comprises: (i) a VH that contains 20 or fewer (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO: 82, and , 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 92; (ii) a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 92; and a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 93. L, (iii) a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO: 92, and a VL containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO: 95, (iv) a VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions, or deletions in the amino acid sequence set forth in SEQ ID NO: 100, , 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 28, and a VL having 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence set forth in SEQ ID NO: 28; (v) 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions in the amino acid sequence set forth in SEQ ID NO: 21;VH containing an insertion or deletion, and VL containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 104; (vi) VH containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 49, and VL containing 20 or less (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) substitutions, insertions or deletions in the amino acid sequence shown in SEQ ID NO: 107.

[0021] In some embodiments of the above aspects, the antibody comprises a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region. In some embodiments of the above aspects, the antibody is modified to reduce or eliminate effector function. In some embodiments of the above aspects, the antibody comprises an aglycosylated human constant region. In some embodiments of the above aspects, the antibody comprises hIgG1agly Fc, hIgG2 SAA Fc, hIgG4(S228P) Fc, or hIgG4(S228P) / G1 agly Fc. In some embodiments of the above aspects, the antibody comprises a human kappa or human lambda light chain constant region. In some embodiments of the above aspects, the antibody is a whole antibody, a single domain antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an Fv, a scFv, a scFv-Fc, a scFv-CH3, a sc(Fv)2, a sc(Fv)2-Fc, a sc(Fv)2-CH3, a diabody, a nanobody, a Fab, and a F(ab')2. In some embodiments of the above aspects, the antibody further comprises a half-life extending moiety. In some embodiments of the above aspects, the antibody further comprises a detectable label (e.g., a fluorescent label). In some embodiments of the above aspects, the antibody further comprises a therapeutic agent. In some embodiments of the above aspects, the antibody further comprises a radiotherapeutic agent. In some embodiments of the above aspects, the antibody further comprises a chemotherapeutic agent.

[0022] In another aspect, provided herein is a pharmaceutical composition comprising an antibody of any one of the above aspects. In another aspect, provided herein is one or more polynucleotides encoding an antibody of any one of the above aspects. The polynucleotide may encode an antibody that binds to its RGD family integrin (e.g., αvβ1, αvβ6, αvβ1+other RGD family integrins) and include nucleic acids encoding the three VH CDRs or VHs of any of the exemplary antibodies 1-20. In other cases, the polynucleotide may encode an antibody that binds to its RGD family integrin (e.g., αvβ1, αvβ6, αvβ1+other RGD family integrins) and include nucleic acids encoding the three VL CDRs or VLs of any of the exemplary antibodies 1-20. In some cases, the polynucleotide may encode an antibody that binds to its RGD family integrin (e.g., αvβ1, αvβ6, αvβ1+other RGD family integrins) and include nucleic acids encoding the three VH CDRs and three VLs of any of the exemplary antibodies 1-20. In yet other cases, the polynucleotide may encode an antibody that binds to the RGD family integrin (e.g., αvβ1, αvβ6, αvβ1+other RGD family integrins) and may include nucleic acids encoding the VH and VL of any of exemplary antibodies 1-20. In another aspect, provided herein is one or more vectors (e.g., expression vector(s)) comprising one or more polynucleotides of the above aspects. In a further aspect, provided herein is a host cell comprising one or more polynucleotides of the above aspects, or one or more vectors (e.g., expression vector(s)) of the above aspects.

[0023] In another aspect, provided herein is a method of making an anti-integrin antibody, the method comprising: (a) culturing a host cell under conditions that allow expression of the antibody; and (b) isolating the antibody. In some embodiments of the above aspect, the method further comprises formulating the antibody as a sterile formulation suitable for administration to a human.

[0024] In another aspect, provided herein is a method of treating or preventing fibrosis in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of an anti-integrin antibody described herein (e.g., Exemplary Antibodies 1-20). In some embodiments of the above aspects, the fibrosis is selected from the group consisting of liver fibrosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, arthrofibrosis, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, Peyronie's disease, progressive massive fibrosis, small airway fibrosis, fibrosis associated with chronic obstructive pulmonary disease, and retroperitoneal fibrosis. In some embodiments, the fibrosis is liver fibrosis. In some embodiments, the fibrosis is idiopathic pulmonary fibrosis. In some embodiments, the fibrosis is scleroderma / systemic sclerosis.

[0025] In another aspect, provided herein is a method of treating or preventing cancer in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of an anti-integrin antibody described herein (e.g., Exemplary Antibodies 1-20). In some embodiments of the above aspects, the cancer is of epithelial origin, and optionally, the epithelial origin cancer is squamous cell carcinoma, adenocarcinoma, transitional cell carcinoma, or basal cell carcinoma. In some embodiments, the cancer is selected from the group consisting of pancreatic cancer, breast cancer, melanoma, prostate cancer, ovarian cancer, cervical cancer, brain and central nervous system tumors, and glioblastoma.

[0026] In another aspect, provided herein is a method of inhibiting platelet aggregation in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of an anti-integrin antibody described herein (e.g., exemplary antibodies 1-20). In some embodiments of the above aspects, the inhibition is for the treatment of acute coronary syndrome.

[0027] In another aspect, provided herein is a method of treating or preventing an ophthalmic disease or disorder in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an anti-integrin antibody described herein (e.g., exemplary antibodies 1-20). In some embodiments of the above aspects, the ophthalmic disease or disorder is selected from the group consisting of age-related macular degeneration (AMD), wet AMD, macular edema, and diabetic retinopathy.

[0028] In another aspect, provided herein is a method of treating or preventing acute kidney injury, acute lung injury, or acute liver injury in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of an anti-integrin antibody described herein (e.g., exemplary antibodies 1-20).

[0029] In another aspect, provided herein is a method of treating or preventing non-alcoholic fatty liver disease (NAFLD) in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of an anti-integrin antibody (e.g., any one or more of exemplary antibodies 1-20) described herein. In some embodiments, the NAFLD is non-alcoholic steatohepatitis (NASH).

[0030] In another aspect, provided herein is a method for identifying an antibody that specifically binds to αvβ1 integrin but not to other integrins from an antibody population, comprising selecting the antibody using guided selection with an induced antibody that is any of the anti-integrin antibodies described herein (e.g., exemplary antibodies 1-20). In some embodiments, the induced antibody comprises the six CDRs of any one of exemplary antibodies 5, 11, and 12. In some embodiments, the induced antibody comprises the VH and / or VL of any one of exemplary antibodies 5, 11, and 12. In some embodiments, the antibody population comprises an antibody library expressed on the surface of a prokaryotic cell. In some embodiments, the antibody population comprises an antibody library expressed on the surface of a eukaryotic cell. In some embodiments, the antibody population comprises an antibody library expressed on the surface of a yeast cell. In some embodiments, the method includes a step of selecting antibodies that bind to one or more polypeptides comprising the extracellular domains of αv and β1, optionally performed in the absence of cations, in the presence of calcium and magnesium, or in the presence of manganese, and optionally, the selection is performed by MACS and / or FACS. In some embodiments, the method further includes depleting antibodies that bind to one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and α4β1. In some embodiments, the method further includes enriching for antibodies that specifically bind to αvβ1 integrin by selecting antibodies that bind to αvβ1 integrin. The selection can be performed in one or more rounds (e.g., one, two, three, four, or five rounds). In some embodiments, the method further includes affinity maturing the selected antibodies.

[0031] In a further aspect, provided herein is a method of identifying an antibody from an antibody population, the method comprising selecting the antibody using guided selection with an derived antibody (e.g., one or more of exemplary antibodies 1-20), the antibody specifically binds to both αvβ1 and αvβ6 integrins and is an anti-integrin antibody described herein. In some embodiments, the derived antibody comprises the six CDRs of any one of exemplary antibodies 5, 11, and 12. In some embodiments, the derived antibody comprises the VH and / or VL of any one of exemplary antibodies 5, 11, and 12. In some embodiments, the antibody population comprises an antibody library expressed on the surface of a prokaryotic cell. In some embodiments, the antibody population comprises an antibody library expressed on the surface of a eukaryotic cell. In some embodiments, the antibody population comprises an antibody library expressed on the surface of a yeast cell. In some embodiments, the method comprises selecting antibodies that bind to one or more polypeptides comprising the extracellular domains of αv and β1 and / or αv and β6, optionally in the absence of cations, in the presence of calcium and magnesium, or in the presence of manganese, and optionally, the selection is performed by MACS and / or FACS. In some embodiments, the method further comprises depleting antibodies that bind to one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ8, α5β1, α8β1, and α4β1. In some embodiments, the method further comprises enriching for antibodies that specifically bind to αvβ1 and αvβ6 integrins by selecting antibodies that bind to αvβ1 and αvβ6 integrins. The selection can be performed in one or more rounds (e.g., one, two, three, four, or five rounds). In some embodiments, the method further comprises affinity maturing the selected antibodies.

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice or test the present invention, exemplary methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present application, including definitions, will control. The materials, methods, and examples are illustrative only and are not intended to be limiting.

[0033] Other features and advantages of the invention will become apparent from the following detailed description, and from the claims. [Brief description of the drawings]

[0034] [Figure 1] A general overview of triage of αvβ1 specific antibodies, αvβ1 / αvβ6 specific antibodies, and antibodies specific for αvβ1+1 or more integrins is provided. [Figure 2A] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2B] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2C] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2D] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2E] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2F] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2G] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2H] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2I] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2J] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 2K] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 3A] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 3B] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 3C] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 3D] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 3E] Examples of observed binding kinetics of αvβ1-specific, non-specific, and partially selective antibodies are shown. [Figure 4A] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4B] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4C] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4D] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4E] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4F] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4G] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4H] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4I] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 4J] Monovalent binding affinity to recombinant αvβ1 is shown. [Figure 5A] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 5B] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 5C] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 5D] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 5E] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6A] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6B] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6C] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6D] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6E] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6F] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6G] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6H] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6I] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 6J] Examples of observed binding titers of αvβ1 specific and partially selective antibodies are shown. [Figure 7] A to E show examples of adhesion inhibition by αvβ1 LAP. [Figure 8] An example of inhibition of adhesion of α4β1 VCAM is shown. [Figure 9] AD provide examples of observed binding to MRC9 (human fibroblasts) and BLO-11 (mouse fibroblasts). [Figure 10] AC show examples of PAI-1 inhibition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] The present disclosure features antibodies that bind to integrins, such as RGD-binding integrins. Antibodies that specifically bind to αvβ1 integrin are provided. In some cases, provided herein are antibodies that bind to αvβ1 integrin but not to other integrins (e.g., these antibodies do not bind to other RGD-binding integrins or other αv or β1-containing integrin heterodimers). Also provided herein are antibodies that bind to both αvβ1 and αvβ6 integrin but not to other integrins (e.g., these antibodies do not bind to other RGD-binding integrins or other αv, β1, or β6-containing integrin heterodimers). In some cases, provided herein are antibodies that bind to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3. The antibodies described herein are useful in the treatment or prevention of disorders such as any fibrotic disease or condition, cancer (eg, epithelial cancer), and eye diseases.

[0036] Integrin αv integrins (αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8) have the ability to bind and activate the pro-fibrotic cytokine transforming growth factor β (TGFβ) and are involved in various fibrotic diseases and cancers. Blocking αv integrins can potentially reduce the downstream effects of TGFβ signaling. It is desirable to generate antibodies against αvβ1 integrin, since it is highly expressed on activated fibroblasts and directly binds to the latency-associated peptide (LAP) of TGFβ1, mediating TGFβ1 activation. However, due to the fact that the αv and β1 subunits exist separately in many integrin dimer pairs, it is very difficult to generate heterodimer-specific antibodies against αvβ1 integrin (see, for example, Reed et al., Science Translational Medicine, 7(288):288ra79(2015); Wilkinson et al., Eur. J Pharmacol., 842(2019)239-247). In fact, no such anti-αvβ1 integrin-specific antibodies have been described in the art.

[0037] The αvβ6 integrin is a member of the RGD-binding integrins. v Although the subunit can form heterodimers with various β subunits (β1, β3, β5, β6, and β8), the β6 subunit can only be expressed as a heterodimer with the αv subunit. The extracellular and cytoplasmic domains of the β6 subunit mediate distinct cellular activities. The extracellular and transmembrane domains have been shown to mediate TGF-β activation and adhesion, whereas the cytoplasmic domain of the β6 subunit contains a unique 11 amino acid sequence that is important in mediating αvβ6-regulated cell proliferation, MMP production, migration, and promotes survival.

[0038] The integrin αv subunit is also known as ITGAV, CD51, MSK8, VNRA, VTNR, vitronectin receptor, or integrin subunit αV. The amino acid sequence of the human integrin αv protein (Uniprot accession number P06756-1) is shown below.

[0039] The integrin β1 subunit is also known as ITGB1, CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA, VLAB, or integrin subunit β1. The amino acid sequence of the human integrin β1 protein (Uniprot accession number P05556-1) is shown below. MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPY ISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLS EGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK (SEQ ID NO: 2)

[0040] The integrin β6 subunit is also known as ITGB6, A11H, or integrin subunit β6. The amino acid sequence of the human integrin β6 protein (Genbank® Accession No. NP_000879.2) is shown below. [ka]

[0041] An exemplary amino acid sequence of a human integrin β3 protein can be found in Genbank® Accession No. NP_000203.2. An exemplary amino acid sequence of a human integrin β5 protein can be found in Genbank® Accession No. NP_002204.2. An exemplary amino acid sequence of a human integrin β8 protein can be found in Genbank® Accession No. NP_002205.1. An exemplary amino acid sequence of a human integrin α5 protein can be found in Genbank® Accession No. NP_002196.4. An exemplary amino acid sequence of a human integrin α8 protein can be found in Genbank® Accession No. NP_001278423.1. An exemplary amino acid sequence of a human integrin αIIB protein can be found in Genbank® Accession No. NP_000410.2.

[0042] The extracellular region of the integrin subunit αV corresponds to amino acids 31 to 993 of SEQ ID NO: 1. The extracellular region of the integrin subunit β1 corresponds to amino acids 21 to 728 of SEQ ID NO: 2.

[0043] Anti-integrin antibodies All of the anti-integrin antibodies of the present disclosure bind to αvβ1. In some cases, the antibody is specific for αvβ1 and does not bind to other integrins. In some cases, the antibody also binds to αvβ6, but does not bind to other integrins. In still other cases, the antibody binds to one or more RGD-binding integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3.

[0044] In some cases, the antibodies of the present disclosure block the interaction of the integrin to which the antibody binds with its ligand. For example, an anti-integrin antibody blocks αvβ1 interaction with its ligand (e.g., LAP and fibronectin). In certain cases, an anti-integrin antibody blocks αvβ6 interaction with its ligand (e.g., LAP and fibronectin). In some cases, the antibodies of the present disclosure are cation-dependent for binding to their target (e.g., calcium and magnesium, or manganese). Examples of such antibodies are exemplary antibodies 1, 2, 4-14, 16, 17, 19, and 20. In some cases, the antibodies of the present disclosure are not cation-dependent for binding to their target. Examples of such antibodies are exemplary antibodies 3, 15, and 18.

[0045] In some cases, the antibodies of the disclosure bind to their target integrins (e.g., αvβ1, αvβ6) on fibroblasts, the cell type responsible for the deposition of extracellular matrix in fibrotic diseases.

[0046] In some cases, the antibodies of the disclosure inhibit a fibroblast TGFβ response.

[0047] In some cases, one or more of the antibodies of the present disclosure are internalized. Examples of such antibodies are exemplary antibodies 4, 5, 17, and 19. An internalized antibody can be used to deliver an agent (e.g., a small molecule or an intracellular antibody) that needs to be delivered to a cell.

[0048] In some cases, one or more of the antibodies of the present disclosure bind to cynomolgus monkey, mouse, or rat αvβ1. Examples of such antibodies are exemplary antibodies 4, 5, 17, and 19.

[0049] In certain cases, the present disclosure features antibodies that specifically bind to human αvβ1 and have one or more (e.g., one, two, three, four, or five) of the following properties: (i) bind to human αvβ1 with high affinity (bivalent affinity) with a KD of ≦20 nM; (ii) block αvβ1 interaction with its ligands (e.g., LAP and fibronectin); (iii) are cation-dependent (e.g., calcium and magnesium, or manganese) or cation-independent for binding to human αvβ1; (iv) bind to αvβ1 on fibroblasts; and (v) inhibit fibroblast TGFβ responses (e.g., as assessed by an LPA-induced PAI-1 assay).

[0050] In some cases, the disclosure features antibodies that specifically bind to both human αvβ1 and human αvβ6 and have one or more (e.g., one, two, three, four, or five) of the following properties: (i) binds to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to human αvβ6 with affinity (bivalent affinity) of 100 nM; (ii) blocks αvβ1 and / or αvβ6 interaction with its ligands (e.g., LAP and fibronectin); (iii) is cation-dependent (e.g., calcium and magnesium, or manganese) for binding to human αvβ1 and / or αvβ6; (iv) binds to αvβ1 on fibroblasts; and (v) inhibits fibroblast TGFβ response (e.g., as assessed by an LPA-induced PAI-1 assay).

[0051] In certain cases, the present disclosure features antibodies that specifically bind to both human αvβ1 and one or more of other RGD-binding integrins and have one or more (e.g., one, two, three, four, or five) of the following properties: (i) bind to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to other RGD-binding integrins with affinity (bivalent affinity) of 100 nM; (ii) block αvβ1 and / or RGD family integrin interactions with their ligands (e.g., LAP and fibronectin); (iii) are cation-dependent (e.g., calcium and magnesium, or manganese) or cation-independent with respect to binding to human αvβ1 and / or RGD-binding integrins; (iv) bind to αvβ1 and / or RGD-binding integrins on fibroblasts; and (v) inhibit fibroblast TGFβ responses (e.g., as assessed by an LPA-induced PAI-1 assay).

[0052] The use of the term "antibody" in this disclosure is meant to encompass whole antibodies, bispecific antibodies, tetravalent antibodies, multispecific antibodies, minibodies, nanobodies, and antibody fragments (as opposed to minibodies, nanobodies, or antibody fragments). In some cases, the anti-integrin antibody of the present disclosure is a whole antibody. In certain examples, the heavy chain constant region of the anti-integrin antibody is a human IgG1, human IgG2, human IgG3, or human IgG4 constant region. In some cases, the light constant region is a human kappa constant region. In other cases, the light constant region is a human lambda constant region. In some cases, the antibodies of the disclosure are engineered to have reduced effector functionality (e.g., by Fc modifications such as N297Q, T299A, etc.; see also Wang, X., Mathieu, M. & Brezski, R J Protein Cell (2018) 9:63. doi.org / 10.1007 / s13238-017-0473-8, incorporated herein by reference). Optionally, the Fc portion of the antibody is hIgG1 Fc, hIgG2 Fc, hIgG3 Fc, hIgG4 Fc, hIgG1agly Fc, hIgG2 SAA Fc, hIgG4(S228P) Fc, or hIgG4(S228P) / G1 agly Fc (in this format, effector function is minimized and the CH1 and CH2 domains are IgG4 with a "fixed" hinge (S228P) and are non-glycosylated. The CH3 domain is hIgG1, or hIgG4(S228P) agly Fc). In one example, the antibody has one of three scaffolds with reduced effector function: hIgG1 agly(N297Q), hIgG2 SAA (see Vafa et al. Methods, 65(1):114-26 (2014)), and hIgG4P / G1 agly (see US2012 / 0100140(A1)).

[0053] For ease of exposition, the anti-integrin antibodies characterized herein are divided into three groups, namely, Groups I-III.

[0054] Group I antibodies are those that bind to αvβ1 integrin but not to other integrins (e.g., other αv-containing or β1-containing or RGD family integrins). Group II antibodies are those that bind to αvβ1 and αvβ6 integrins but not to other integrins. Finally, Group III antibodies bind to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1 and αIIBβ3. These three antibody groups are described in more detail below.

[0055] A. Group I (anti-αvβ1 integrin specific antibody) Many publications have suggested the challenges associated with generating antibodies specific to αvβ1 integrin, due in part to the fact that αv and β1 subunits exist separately in many integrin dimer pairs (Reed et al., Sci Transl Med., 7:288 (2015)). The present inventors have succeeded in generating such anti-αvβ1 integrin specific antibodies.

[0056] Thus, the present disclosure provides antibodies that specifically bind to αvβ1 integrin and not to other integrins. In some cases, the antibodies do not bind to other αv or β1-containing integrin heterodimers. In some cases, the anti-αvβ1 antibodies do not bind to other RGD integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3 integrins). All of these antibodies bind to human αvβ1 integrin. Such antibodies include exemplary antibodies 1-10 that bind to human αvβ1 with high affinity (bivalent affinity) with KD≦20 nM.

[0057] Exemplary Antibody 1 Exemplary Antibody 1 specifically binds to human αvβ1. The amino acid sequences of the complementarity determining regions (CDRs) and mature heavy and light chain variable regions of exemplary Antibody 1 are provided below. [Table 3] Heavy chain variable region (VH): QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARQQRHRRDYDYYYGMDVWGQGTTVTVSS (SEQ ID NO: 11) Light chain variable region (VL): EIVLTQSPGTLSLSPGERATLSCRASQSVSSDYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAYSLPPTFGGGTKVEIK (SEQ ID NO: 12)

[0058] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs of Exemplary Antibody 1, and a VL that includes the three VL CDRs. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database (www.bioinf.org.uk / abysis / sequence_input / key_annotation / key_annotation.cgi).

[0059] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 3, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10.

[0060] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 11. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 12. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 11 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 12. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 11, and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 12. In yet another example, the anti-αvβ1 antibody comprises a VH that is identical to the amino acid sequence set forth in SEQ ID NO: 11, and a VL that is identical to the amino acid sequence set forth in SEQ ID NO: 12.

[0061] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:11 and a VL having the amino acid sequence set forth in SEQ ID NO:12.

[0062] Exemplary Antibody 2 Exemplary Antibody 2 specifically binds to human αvβ1. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary Antibody 2 are provided below. [Table 4] VH: QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGPTRGDGTRVYYYGMDVWGQGTTVTVSS (SEQ ID NO: 21) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYHHPFTFGGGTKVEIK (SEQ ID NO: 22)

[0063] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of Exemplary Antibody 2. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, Enhanced Chothia, Contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0064] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 20. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 13, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 20.

[0065] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 21. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 22. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 21 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 22. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 21 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 22. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 21 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 22.

[0066] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:21 and a VL having the amino acid sequence set forth in SEQ ID NO:22.

[0067] Exemplary Antibody 3 Exemplary antibody 3 specifically binds to human αvβ1. The antibody exhibits cation-independent binding to its target. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 3 are provided below. [Table 5] VH: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARETNYYRGGPAFDIWGQGTMVTVSS (SEQ ID NO: 27) VL: DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQVLGTPPWTFGGGTKVEIK (SEQ ID NO: 28)

[0068] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of Exemplary Antibody 3. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, Enhanced Chothia, Contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0069] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 23, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 24, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 25, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 26. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 3, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 23, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 24, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 25, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 26.

[0070] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 27. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 28. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 27 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 28. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 27 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 28. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 27 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 28.

[0071] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:27 and a VL having the amino acid sequence set forth in SEQ ID NO:28.

[0072] Exemplary Antibody 4 Exemplary Antibody 4 specifically binds human αvβ1 and also binds cynomolgus monkey, mouse, and rat αvβ1. Exemplary Antibody 4 is internalized. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary Antibody 4 are provided below. [Table 6-1] [Table 6-2] VH: QVQLVESGGGLVQPGGSLRLSCAASGFTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARQQRHRRDYDYYYGMDVWGQGTTVTVSS (SEQ ID NO: 30) VL: EIVLTQSPGTLSLSPGERATLSCRASQSVSSDYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQAYSLPPTFGGGTKVEIK (SEQ ID NO: 12)

[0073] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of Exemplary Antibody 4. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, Enhanced Chothia, Contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0074] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 3, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10.

[0075] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 30. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 12. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 30 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 12. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 30 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 12. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 30 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 12.

[0076] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 30 and a VL having the amino acid sequence set forth in SEQ ID NO: 12.

[0077] Exemplary Antibody 5 Exemplary antibody 5 specifically binds human αvβ1 and also binds cynomolgus monkey, mouse, and rat αvβ1. Exemplary antibody 5 is internalized. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 5 are provided below. [Table 7] VH: EVQLVESGGGVVQPGRSLRLSCAASGFTFKYYGMHWVRQAPGKGLEWVASIWYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGPTRGDGTRVYYYGMDVWGQGTTVTVSS (SEQ ID NO: 35) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYHHPFTFGGGTKVEIK (SEQ ID NO: 22)

[0078] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 5. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0079] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 20. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 31, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 20.

[0080] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 35. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 22. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 35 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 22. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 35 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 22. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 35 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 22.

[0081] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 35 and a VL having the amino acid sequence set forth in SEQ ID NO: 22.

[0082] Exemplary Antibody 6 Exemplary Antibody 6 specifically binds to human αvβ1. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary Antibody 6 are provided below. [Table 8-1] [Table 8-2] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGRNRGDSSLSGIDVWGQGTTVTVSS (SEQ ID NO: 44) VL: DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQYSDITFGGGTKVEIK (SEQ ID NO: 45)

[0083] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 6. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0084] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 41, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 43. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 41, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 43.

[0085] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 44. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 45. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 45. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 45. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 45.

[0086] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 44 and a VL having the amino acid sequence set forth in SEQ ID NO: 45.

[0087] Exemplary Antibody 7 Exemplary Antibody 7 specifically binds to human αvβ1. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary Antibody 7 are provided below. [Table 9] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGPSRGDALAEYFQHWGQGTTVTVSS (SEQ ID NO: 49) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQLVNYPPITFGGGTKVEIK (SEQ ID NO: 50)

[0088] In some cases, the anti-αvβ1 antibody comprises a VH that comprises the three VH CDRs and a VL that comprises the three VL CDRs of Exemplary Antibody 7. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0089] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 46, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 46, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48.

[0090] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 49. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 50. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 50. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 50. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 50.

[0091] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:49 and a VL having the amino acid sequence set forth in SEQ ID NO:50.

[0092] Exemplary Antibody 8 Exemplary Antibody 8 specifically binds to human αvβ1. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary Antibody 8 are provided below. [Table 10] VH: EVQLVESGGGLVQPGGSLRLSCAASGFTFYDYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGLWSTEVRYYYMDVWGKGTTVTVSS (SEQ ID NO: 57) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSNAWPFTFGGGTKVEIK (SEQ ID NO: 58)

[0093] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 8. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0094] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 52, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 54, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 51, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 53, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56.

[0095] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 57. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 58. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 57 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 58. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 57 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 58. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 57 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 58.

[0096] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:57 and a VL having the amino acid sequence set forth in SEQ ID NO:58.

[0097] Exemplary Antibody 9 Exemplary Antibody 9 specifically binds to human αvβ1. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary Antibody 9 are provided below. [Table 11] VH: EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGLWSTEVRYYYMDVWGKGTTVTVSS (SEQ ID NO: 61) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSNAWPFTFGGGTKVEIK (SEQ ID NO: 58)

[0098] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs of exemplary antibody 9, and a VL that includes the three VL CDRs. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0099] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 60, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56.

[0100] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 61. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 58. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 61 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 58. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 61 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 58. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 61 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 58.

[0101] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:61 and a VL having the amino acid sequence set forth in SEQ ID NO:58.

[0102] Exemplary Antibody 10 Exemplary antibody 10 specifically binds to human αvβ1. The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 10 are provided below. [Table 12] VH: EVQLVESGGGLVQPGGSLRLSCAASGFTFGEYSMFWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGLWSTEVRYYYMDVWGKGTTVTVSS (SEQ ID NO: 64) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSNAWPFTFGGGTKVEIK (SEQ ID NO: 58)

[0103] In some cases, the anti-αvβ1 antibody comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 10. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0104] In one example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 63, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 54, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56. In another example, the anti-αvβ1 antibody of the present disclosure comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 62, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 53, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56.

[0105] In some cases, the anti-αvβ1 antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 64. In some cases, the anti-αvβ1 antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 58. In one case, the anti-αvβ1 antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 64 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 58. In another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 64 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 58. In yet another example, the anti-αvβ1 antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 64 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 58.

[0106] In certain cases, an antibody of the present disclosure that binds to αvβ1 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:64 and a VL having the amino acid sequence set forth in SEQ ID NO:58.

[0107] B. Group II (antibodies that bind to both αvβ1 and αvβ6 integrins but not to other integrins) The present disclosure further provides antibodies that bind to both αvβ1 and αvβ6 integrins. In some cases, the antibodies do not bind to other integrins. In some cases, the antibodies do not bind to RGD-binding integrins other than αvβ1 and αvβ6 integrins (e.g., αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3). All antibodies in Group II bind to human αvβ1 and human αvβ6 integrins. Such antibodies include sequences of exemplary antibodies 11-14, which bind to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to human αvβ6 with affinity (bivalent affinity) of 100 nM.

[0108] Exemplary Antibody 11 Exemplary antibody 11 specifically binds to human αvβ1 and αvβ6, but does not bind to other integrins (e.g., other RGD family of integrins). The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 11 are provided below. [Table 13-1] [Table 13-2] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGRNRGDSSLSGIDVWGQGTTVTVSS (SEQ ID NO: 44) VL: DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQYDDITFGGGTKVEIK (SEQ ID NO: 68)

[0109] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 11. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions. These CDRs can be determined, for example, using the AbYsis database.

[0110] In one example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 65, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 67. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 65, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 67.

[0111] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 44. In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 68. In one case, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 68. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 68. In yet another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 68.

[0112] In certain cases, an antibody that binds to both human αvβ1 and αvβ6 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:44 and a VL having the amino acid sequence set forth in SEQ ID NO:68.

[0113] Exemplary Antibody 12 Exemplary antibody 12 specifically binds to human αvβ1 and αvβ6, but does not bind to other integrins (e.g., other RGD family of integrins). The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 12 are provided below. [Table 14] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGRNRGDSSLSGIDVWGQGTTVTVSS (SEQ ID NO: 44) VL: DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQYIDITFGGGTKVEIK (SEQ ID NO: 70)

[0114] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 12. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0115] In one example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 65, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 69. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 65, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 69.

[0116] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 44. In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 70. In one case, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 70. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 70. In yet another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 44 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 70.

[0117] In certain cases, an antibody that binds to both human αvβ1 and αvβ6 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 44 and a VL having the amino acid sequence set forth in SEQ ID NO: 70.

[0118] Exemplary Antibody 13 Exemplary antibody 13 specifically binds to human αvβ1 and αvβ6, but does not bind to other integrins (e.g., other RGD family of integrins). The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 13 are provided below. [Table 15] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGPSRGDALAEYFQHWGQGTTVTVSS (SEQ ID NO: 49) VL: EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQLTNHPPIAFGGGTKVEIK (SEQ ID NO: 72)

[0119] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 13. The six CDRs can be based on any definition known in the art, including but not limited to the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0120] In one example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 46, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 46, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 18, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71.

[0121] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 49. In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 72. In one case, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 72. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 72. In yet another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 72.

[0122] In certain cases, an antibody that binds to both human αvβ1 and αvβ6 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:49 and a VL having the amino acid sequence set forth in SEQ ID NO:72.

[0123] Exemplary Antibody 14 Exemplary antibody 14 specifically binds to human αvβ1 and αvβ6, but does not bind to other integrins (e.g., other RGD family of integrins). The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 14 are provided below. [Table 16-1] [Table 16-2] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARERGNRGDTPRYYYMDVWGKGTTVTVSS (SEQ ID NO: 76) VL: DIQMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSLVTPFTFGGGTKVEIK (SEQ ID NO: 77)

[0124] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 14. The six CDRs can be based on any definition known in the art, including but not limited to the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0125] In one example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 73, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 74, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 75. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 73, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 74, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 75.

[0126] In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 76. In some cases, an antibody that binds to both human αvβ1 and αvβ6 comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 77. In one case, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 76 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 77. In another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 76 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 77. In yet another example, an antibody that binds to both human αvβ1 and αvβ6 comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 76 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 77.

[0127] In certain cases, an antibody that binds to both human αvβ1 and αvβ6 is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 76 and a VL having the amino acid sequence set forth in SEQ ID NO: 77.

[0128] C. Group III (antibodies that bind to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3 integrin) The disclosure further features antibodies that bind to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3. In some cases, the antibodies do not bind to integrins other than RGD-binding integrins. Such antibodies include sequences of exemplary antibodies 15-20 that bind to human αvβ1 with high affinity (bivalent affinity) with a KD≦20 nM and to other RGD-binding integrins with affinity (bivalent affinity) of 100 nM.

[0129] Exemplary Antibody 15 Exemplary antibody 15 specifically binds to human αvβ1 and at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) other RGD family integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). The antibody exhibits cation-independent binding to its target. The amino acid sequences of the CDRs of exemplary antibody 15, as well as the mature heavy and light chain variable regions, are provided below. [Table 17-1] [Table 17-2] VH: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDRSGIAGRRWVYYYGMDVWGQGTTVTVSS (SEQ ID NO: 82) VL: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNLPYTFGGGTKVEIK (SEQ ID NO: 83)

[0130] In some cases, a Group III antibody (i.e., an antibody that binds to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) comprises a VH that comprises the three VH CDRs and a VL that comprises the three VL CDRs of exemplary antibody 15. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0131] In one example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO:4, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO:78, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO:79, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO:80, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO:81. In another example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO:3, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO:5, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO:78, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO:79, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO:80, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO:81.

[0132] In some cases, a Group III antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 82. In some cases, a Group III antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 83. In one case, a Group III antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 82 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 83. In another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 82 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 83. In yet another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 82 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 83.

[0133] In certain cases, a Group III antibody is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 82 and a VL having the amino acid sequence set forth in SEQ ID NO: 83.

[0134] Exemplary Antibody 16 Exemplary antibody 16 specifically binds to human αvβ1 and at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) other RGD family integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 16 are provided below. [Table 18] VH: EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGPRSRGDGPSNYYYMDVWGQGTLVTVSS (SEQ ID NO: 92) VL: DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYHSFSFTFGGGTKVEIK (SEQ ID NO: 93)

[0135] In some cases, a Group III antibody (i.e., an antibody that binds to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) comprises a VH that comprises the three VH CDRs and a VL that comprises the three VL CDRs of exemplary antibody 16. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0136] In one example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 87, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 88, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91. In another example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 88, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91.

[0137] In some cases, a Group III antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 92. In some cases, a Group III antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 93. In one case, a Group III antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 92 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 93. In another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 92 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 93. In yet another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 92 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 93.

[0138] In certain cases, a Group III antibody is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 92 and a VL having the amino acid sequence set forth in SEQ ID NO: 93.

[0139] Exemplary Antibody 17 Exemplary antibody 17 specifically binds to human αvβ1 and at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) other RGD family integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). Exemplary antibody 17 also binds to cynomolgus monkey, mouse, and rat αvβ1. Exemplary antibody 17 is internalized. In some cases, the antibody specifically binds to αvβ1 and αvβ3. The amino acid sequences of the CDRs of exemplary antibody 17, as well as the mature heavy and light chain variable regions, are provided below. [Table 19-1] [Table 19-2] VH: EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGPRSRGDGPSNYYYMDVWGQGTLVTVSS (SEQ ID NO: 92) VL: DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYRPLPPTFGGGTKVEIK (SEQ ID NO: 95)

[0140] In some cases, a Group III antibody (i.e., an antibody that binds to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 17. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0141] In one example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 87, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 88, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94. In another example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 88, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94.

[0142] In some cases, a Group III antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 92. In some cases, a Group III antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 95. In one case, a Group III antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 92 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 95. In another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 92 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 95. In yet another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 92 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 95.

[0143] In certain cases, a Group III antibody is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 92 and a VL having the amino acid sequence set forth in SEQ ID NO: 95.

[0144] Exemplary Antibody 18 Exemplary antibody 18 specifically binds to human αvβ1 and at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) other RGD family integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). In some cases, the antibody specifically binds to αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8. The antibody exhibits cation-independent binding to its target. The amino acid sequences of the CDRs of exemplary antibody 18, as well as the mature heavy and light chain variable regions, are provided below. [Table 20] VH: QVQLVQSGAEVKKPGASVKVSCKASGYTFRSFYMHWVRQAPGQGLEWMGVINPSLGSTGYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARETNYYRGGPAFDIWGQGTMVTVSS (SEQ ID NO: 100) VL: DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQVLGTPPWTFGGGTKVEIK (SEQ ID NO: 28)

[0145] In some cases, a Group III antibody (i.e., an antibody that binds to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) comprises a VH that includes the three VH CDRs and a VL that includes the three VL CDRs of exemplary antibody 18. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0146] In one example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO:97, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO:99, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO:23, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO:24, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO:25, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO:26. In another example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO:96, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO:98, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO:23, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO:24, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO:25, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO:26.

[0147] In some cases, a Group III antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 100. In some cases, a Group III antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 28. In one case, a Group III antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 100 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO:28. In another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 100 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 28. In yet another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 100 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 28.

[0148] In certain cases, a Group III antibody is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO: 100 and a VL having the amino acid sequence set forth in SEQ ID NO: 28.

[0149] Exemplary Antibody 19 Exemplary antibody 19 specifically binds to human αvβ1 and at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) other RGD family integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). Exemplary antibody 19 also binds to cynomolgus monkey, mouse, and rat αvβ1. Exemplary antibody 19 is internalized. In some cases, the antibody specifically binds to αvβ1 and αvβ8. The amino acid sequences of the CDRs of exemplary antibody 19, as well as the mature heavy and light chain variable regions, are provided below. [Table 21] VH: QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGPTRGDGTRVYYYGMDVWGQGTTVTVSS (SEQ ID NO: 21) VL: DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYVAFPRTFGGGTKVEIK (SEQ ID NO: 104)

[0150] In some cases, a Group III antibody (i.e., an antibody that binds to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) comprises a VH that comprises the three VH CDRs and a VL that comprises the three VL CDRs of exemplary antibody 19. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0151] In one example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 101, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 102, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 103. In another example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 13, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 101, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 102, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 103.

[0152] In some cases, a Group III antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 21. In some cases, a Group III antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 104. In one case, a Group III antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 21 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 104. In another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 21 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 104. In yet another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 21 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 104.

[0153] In certain cases, a Group III antibody is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:21 and a VL having the amino acid sequence set forth in SEQ ID NO:104.

[0154] Exemplary Antibody 20 Exemplary antibody 20 specifically binds to human αvβ1 and at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) other RGD family integrins (e.g., αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). The amino acid sequences of the CDRs, and mature heavy and light chain variable regions of exemplary antibody 20 are provided below. [Table 22] VH: QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGPSRGDALAEYFQHWGQGTTVTVSS (SEQ ID NO: 49) VL: EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLSLHPPYTFGGGTKVEIK (SEQ ID NO: 107)

[0155] In some cases, a Group III antibody (i.e., an antibody that binds to αvβ1 integrin and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) comprises a VH that comprises the three VH CDRs and a VL that comprises the three VL CDRs of exemplary antibody 20. The six CDRs can be based on any definition known in the art, such as, but not limited to, the Kabat, Chothia, enhanced Chothia, contact, IMGT, or Honegger definitions.

[0156] In one example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 46, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 105, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 80, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 106. In another example, a Group III antibody comprises (i) a VH comprising a VHCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a VHCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a VHCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 46, and (ii) a VL comprising a VLCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 105, a VLCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 80, and a VLCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 106.

[0157] In some cases, a Group III antibody comprises a VH that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 49. In some cases, a Group III antibody comprises a VL that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 107. In one case, a Group III antibody comprises a VH that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 107. In another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 107. In yet another example, a Group III antibody comprises a VH that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 49 and a VL that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 107.

[0158] In certain cases, a Group III antibody is an antibody that competes with or binds to the same epitope as a reference antibody having a VH having the amino acid sequence set forth in SEQ ID NO:49 and a VL having the amino acid sequence set forth in SEQ ID NO:107.

[0159] antibody fragment Antibody fragments (e.g., Fab, Fab', F(ab')2, Facb, and Fv) may be prepared by proteolytic digestion of whole antibodies. For example, antibody fragments can be obtained by treating whole antibodies with enzymes such as papain, pepsin, or plasmin. Papain digestion of whole antibodies produces F(ab)2 or Fab fragments, pepsin digestion of whole antibodies produces F(ab')2 or Fab', and plasmin digestion of whole antibodies produces Facb fragments.

[0160] Alternatively, antibody fragments can be produced recombinantly. For example, a nucleic acid encoding the antibody fragment of interest can be constructed, introduced into an expression vector, and expressed in a suitable host cell. See, e.g., Co, MS et al., J. Immunol., 152:2968-2976 (1994); Better, M. and Horwitz, AH, Methods in Enzymology, 178:476-496 (1989); Pluckthun, A. and Skerra, A., Methods in Enzymology, 178:476-496 (1989); Lamoyi, E., Methods in Enzymology, 121:652-663 (1989); Rousseaux, J. et al., Methods in Enzymology, (1989) 121:663-669 (1989); and Bird, RE et al., TIBTECH, 9:132-137 (1991). Antibody fragments can be expressed in and secreted from E. coli, allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from antibody phage libraries. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab)2 fragments (see Carter et al., Bio / Technology, 10:163-167 (1992)). According to another approach, F(ab')2 fragments can be directly isolated from recombinant host cell culture. Fab and F(ab')2 fragments with increased in vivo half-lives that contain salvage receptor binding epitope residues are described in U.S. Pat. No. 5,869,046.

[0161] Mini Body Minibodies of any of the antibodies described herein include diabodies, single chain (scFv), and single chain (Fv)2 (sc(Fv)2). In some cases, the minibody is fused to human Fc or the CH3 domain of human Fc. For example, an scFv or sc(Fv)2 that binds αvβ1 or αvβ1 and αvβ6 may be fused to human IgG1 Fc or human IgG1 CH3 domain. These domains may be modified to reduce effector function. These domains may be modified to reduce or prevent post-translational modifications (e.g., glycosylation).

[0162] A "diabody" is a bivalent minibody constructed by gene fusion (see, for example, Holliger, P. et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993); EP404,097; WO93 / 11161). A diabody is a dimer composed of two polypeptide chains. The VL and VH domains of each polypeptide chain of a diabody are linked by a linker. The number of amino acid residues constituting the linker can be 2 to 12 residues (e.g., 3 to 10 residues or 5 or about 5 residues). The linker of the polypeptides in a diabody is typically too short so that the VL and VH cannot bind to each other. Thus, the VL and VH encoded in the same polypeptide chain cannot form a single-chain variable region fragment, but instead form a dimer with different single-chain variable region fragments. As a result, a diabody has two antigen-binding sites.

[0163] scFv is a single-chain polypeptide antibody obtained by linking VH and VL with a linker (see, for example, Huston et al., Proc. Natl. Acad. Sci. USA, 85:5879-5883 (1988), and Pluckthun, "The Pharmacology of Monoclonal Antibodies" Vol. 113, Ed Resenburg and Moore, Springer Verlag, New York, pp. 269-315, (1994)). The order of VH and VL to be linked is not particularly limited and may be arranged in any order. Examples of the arrangement include [VH] linker [VL], or [VL] linker [VH]. The H chain V region and L chain V region in scFv may be derived from any anti-integrin antibody described herein (e.g., exemplary antibodies 1 to 20).

[0164] sc(Fv)2 is a minibody in which two VHs and two VLs are linked by a linker to form a single chain (Hudson, et al., J. Immunol. Methods, (1999) 231:177-189 (1999)). sc(Fv)2 can be prepared, for example, by connecting scFvs with a linker. The sc(Fv)2 of the present invention preferably includes an antibody in which two VHs and two VLs are arranged in the order of VH, VL, VH, and VL ([VH] linker [VL] linker [VH] linker [VL]) from the N-terminus of a single-chain polypeptide, but the order of the two VHs and two VLs is not limited to the above arrangement, and they can be arranged in any order. Examples of arrangements are listed below: [VL] linker [VH] linker [VH] linker [VL] [VH] linker [VL] linker [VL] linker [VH] [VH] linker [VH] linker [VL] linker [VL] [VL] linker [VL] linker [VH] linker [VH] [VL] linker [VH] linker [VL] linker [VH].

[0165] Typically, three linkers are required when four antibody variable regions are linked, and the linkers used may be the same or different. There is no particular limitation on the linker linking the VH and VL regions of the minibody. In some embodiments, the linker is a peptide linker. Any single-chain peptide containing about 3 to 25 residues (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18) can be used as the linker. Examples of such peptide linkers include Ser; Gly Ser; Gly Gly Ser; Ser Gly Gly; Gly Gly Gly Ser (SEQ ID NO: 108); Ser Gly Gly Gly (SEQ ID NO: 109); Gly Gly Gly Gly Ser (SEQ ID NO: 110); Ser Gly Gly Gly Gly (SEQ ID NO: 111); Gly Gly Gly Gly Gly Ser (SEQ ID NO: 112); Ser Gly Gly Gly Gly Gly (SEQ ID NO: 113); Gly Gly Gly Gly Gly Gly Ser (SEQ ID NO: 114); Ser Gly Gly Gly Gly Gly Gly (SEQ ID NO: 115); (Gly Gly Gly Gly Ser) n (SEQ ID NO:110) n (n is an integer of 1 or more); and (Ser Gly Gly Gly Gly) n (SEQ ID NO:111) n (n is an integer of 1 or more).

[0166] In certain embodiments, the linker is a synthetic compound linker (chemical crosslinker). Examples of commercially available crosslinkers include N-hydroxysuccinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS3), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES), and bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone (sulfo-BSOCOES).

[0167] The amino acid sequences of the VH or VL in a minibody can include modifications such as substitutions, deletions, additions, and / or insertions. For example, the modifications can be in one or more of the framework regions of an antibody described herein (e.g., Exemplary Antibodies 1-20). In certain embodiments, the modifications involve 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in one or more framework regions of the VH and / or VL domains of the minibody. Such substitutions are made to improve the binding and / or functional activity of the minibody. In other embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids of the FR of the antibodies described herein may be deleted or added, so long as there is binding and / or functional activity of αvβ1 (and binding to αvβ6, or binding to one or more of αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3) when VH and VL are associated.

[0168] Bispecific or multispecific antibodies A multispecific antibody is an antibody that has binding specificity for two or more different epitopes. A bispecific antibody is an antibody that has binding specificity for two different epitopes of one antigen or two different antigens. An exemplary bispecific antibody may bind to two different epitopes of the αvβ1 protein. Other such antibodies may combine an αvβ1 binding site with another protein (e.g., αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, αIIBβ3) binding site. In some cases, the bispecific antibody comprises a first VH and a first VL that specifically binds αvβ1, and a second VH and a second VL that specifically binds αvβ6. In other cases, the bispecific antibody comprises a first VH and a first VL that specifically binds αvβ1, and a second VH and a second VL that specifically binds both αvβ1 and αvβ6. In some cases, the bispecific antibody comprises a first VH and a first VL that specifically binds to αvβ1, and a second VH and a second VL that specifically binds to one or more of αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3. In still other cases, the bispecific antibody comprises a first VH and a first VL that specifically binds to both αvβ1 and αvβ6, and a second VH and a second VL that specifically binds to one or more of αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3. Bispecific antibodies can be prepared as full-length antibodies or low molecular weight forms thereof (e.g., F(ab')2 bispecific antibodies, scFv bispecific antibodies, sc(Fv)2 bispecific antibodies, diabody-type bispecific antibodies).

[0169] Traditional production of full-length bispecific antibodies is based on the co-expression of two immunoglobulin heavy-light chain pairs, with the two chains having different specificities (Millstein et al., Nature, 305:537-539 (1983)). In another approach, antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences. DNA encoding the immunoglobulin heavy chain fusions, and optionally the immunoglobulin light chain, are inserted into separate expression vectors and co-transfected into a suitable host cell. This allows more flexibility in adjusting the ratio of the three polypeptide fragments. However, it is possible to insert the coding sequences of two or all three polypeptide chains into a single expression vector, provided that expression of at least two polypeptide chains in equal ratios results in high yields.

[0170] According to another approach, described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. A preferred interface is H3 The method comprises replacing one or more small amino acid side chains from the interface of a first antibody molecule with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of a second antibody molecule by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). This provides a mechanism for increasing the yield of heterodimers over other undesired end products such as homodimers.

[0171] Methods for producing bispecific antibodies are well known in the art. See, for example, Spasevska I, Duong MN, Klein C, Dumontet C (2015) Advances in Bispecific Antibodies Engineering: Novel Concepts for Immunotherapies.J. See Blood Disord Transfus 6:243. Doi:10.4172 / 2155-9864.1000243 and Husain, B. & Ellerman, D. BioDrugs (2018) 32:441. doi.org / 10.1007 / s40259-018-0299-9.

[0172] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be linked to avidin, and the other to biotin. Heteroconjugate antibodies can be produced using any convenient cross-linking method.

[0173] "Diabody" technology provides an alternative mechanism for making bispecific antibody fragments. These fragments contain a VH connected to a VL by a linker that is too short to allow pairing between the two domains on the same chain. Thus, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites.

[0174] Multivalent antibodies A multivalent antibody may be internalized (and / or catabolized) faster than a bivalent antibody by cells expressing the antigen to which the antibody binds (e.g., αvβ1, αvβ1, and αvβ6). Any of the antibodies described herein may be a multivalent antibody (e.g., a tetravalent antibody) having three or more antigen binding sites, which may be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The antibodies described herein may comprise a dimerization domain and three or more antigen binding sites. Exemplary dimerization domains include (or consist of) an Fc region or a hinge region. The antibodies described herein may comprise (or consist of) from three to about eight (e.g., four) antigen binding sites. A multivalent antibody optionally comprises at least one polypeptide chain (e.g., at least two polypeptide chains), where the polypeptide chain(s) comprise two or more variable domains. For example, the polypeptide chain(s) may comprise VD1-(X1) n -VD2-(X2) n -Fc, where VD1 is a first variable domain, VD2 is a second variable domain, Fc is the polypeptide chain of the Fc region, X1 and X2 represent amino acids or peptide spacers, and n is 0 or 1.

[0175] Conjugated antibodies The antibodies disclosed herein can be coupled to polymers (e.g., polyethylene glycol (PEG), PEG-modified polyethyleneimine (PEI) (PEI-PEG), polyglutamic acid (PGA) (N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers), hyaluronic acid, radioactive materials (e.g., 90 Y, 131 I) Conjugated antibodies may be attached to a variety of molecules including fluorescent substances, luminescent substances, haptens, enzymes, metal chelates, and macromolecular substances such as drugs.

[0176] In certain embodiments, the antibodies described herein are modified with a moiety that improves their stabilization and / or retention in the circulation, e.g., at least 1.5-fold, 2-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, or 50-fold, e.g., in blood, serum, or other tissues. For example, the antibodies described herein can be associated (e.g., conjugated) with a polymer, e.g., a substantially non-antigenic polymer, such as a polyalkylene oxide or polyethylene oxide. Suitable polymers vary substantially by weight. Polymers having molecular number average weights ranging from about 200 to about 35,000 daltons (or about 1,000 to about 15,000, and 2,000 to about 12,500) can be used. For example, the antibodies described herein can be conjugated to a water-soluble polymer, e.g., a hydrophilic polyvinyl polymer, e.g., polyvinyl alcohol or polyvinylpyrrolidone. Examples of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycol, polyoxyethylenated polyols, their copolymers and their block copolymers, provided that the water solubility of the block copolymers is maintained. Further useful polymers include polyoxyalkylenes (such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene), polymethacrylates, carbomers, and branched or unbranched polysaccharides.

[0177] The above-mentioned conjugated antibodies can be prepared by chemically modifying the antibodies described herein or their low molecular weight forms. Methods for modifying antibodies are well known in the art (e.g., US 5,057,313 and US 5,156,840).

[0178] Antibodies with reduced effector function The interaction of antibodies and antibody-antigen complexes with immune system cells induces various responses, referred to herein as effector functions. Immune-mediated effector functions include two major mechanisms: antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Both of these are mediated by the constant region of the immunoglobulin protein. Thus, the antibody Fc domain is the moiety that defines the interaction with immune effector mechanisms.

[0179] IgG antibodies activate effector pathways of the immune system by binding to members of the family of cell surface Fcγ receptors and C1q of the complement system. Ligation of effector proteins by clustered antibodies induces a variety of responses, including release of inflammatory cytokines, modulation of antigen production, endocytosis, and cell killing. These responses can lead to undesirable side effects such as inflammation and elimination of antigen-bearing cells. Thus, the present invention further relates to anti-integrin binding proteins, including antibodies with reduced effector function (e.g., anti-αvβ1, anti-αvβ1 and αvβ6 antibodies).

[0180] The effector function of the antibody of the present invention may be determined using one of many known assays. The effector function of the antibody may be reduced compared to a second antibody. In some embodiments in which the antibody of interest is modified to reduce effector function, the second antibody may be an unmodified or parent version of the antibody (e.g., exemplary antibodies 1-20 (e.g., IgG1, IgG2, IgG3) with a wild-type Fc region).

[0181] Effector functions include ADCC, in which an antibody binds to Fc receptors on cytotoxic T cells, natural killer (NK) cells, or macrophages, resulting in cell death, and CDC, which is cell death induced by activation of the complement cascade (reviewed in Daeron, Annu. Rev. Immunol., 15:203-234 (1997); Ward and Ghetie, Therapeutic Immunol., 2:77-94 (1995); and Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991)). Such effector functions generally require combining an Fc region with a binding domain (e.g., an antibody variable domain) and can be assessed using standard assays known in the art (see, e.g., WO05 / 018572, WO05 / 003175, and US6,242,195).

[0182] Effector functions can be avoided by using antibody fragments lacking the Fc domain, such as Fab, Fab'2, or single chain Fv. An alternative is to use IgG4 subtype antibodies, which bind to FcγRI but do not bind well to C1q and FcγRII and RIII. However, IgG4 antibodies are less stable at low pH compared to IgG1 antibodies and may form aggregates. The stability of IgG4 antibodies has been reported (Kabat et al., Sequences of proteins of immunological interest, 1991, 5 thThe stability of IgG4 antibodies can be improved by replacing arginine at position 409 (according to the EU index proposed by the ed.) with any one of lysine, methionine, threonine, leucine, valine, glutamic acid, asparagine, phenylalanine, tryptophan, or tyrosine. Alternatively and / or additionally, the stability of IgG4 antibodies can be improved by replacing the CH3 domain of the IgG4 antibody with the CH3 domain of an IgG1 antibody, or by replacing the CH2 and CH3 domains of IgG4 with the CH2 and CH3 domains of IgG1. Thus, anti-integrin antibodies of the invention that are of IgG4 isotype may include a modification at position 409 and / or replacement of the CH2 and / or CH3 domains with IgG1 domains to increase the stability of the antibody while reducing the effector function. The IgG2 subtype also has reduced binding to Fc receptors, but retains significant binding to the H131 allotype of FcγRIIa and C1q. Therefore, further alterations of the Fc sequence may be required to eliminate binding to all Fc receptors and C1q.

[0183] Some antibody effector functions, including ADCC, are mediated by Fc receptors (FcRs) that bind the Fc region of an antibody. The affinity of an antibody for a particular FcR, and therefore the effector activity mediated by the antibody, can be modulated by altering the amino acid sequence and / or post-translational modifications of the antibody's Fc and / or constant regions.

[0184] FcRs are defined by their specificity for immunoglobulin isotypes. Fc receptors for IgG antibodies are termed FcγR, Fc receptors for IgE are termed FcεR, Fc receptors for IgA are termed FcαR, etc. Three subclasses of FcγR have been identified: FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). Both FcγRII and FcγRIII come in two types: FcγRIIa (CD32a) and FcγRIIB (CD32b), and FcγRIIIA (CD16a) and FcγRIIIB (CD16b). Each FcγR subclass is encoded by two or three genes, and alternative RNA splicing results in multiple transcripts, so a wide diversity in FcγR isoforms exists. For example, FcγRII (CD32) includes isoforms IIa, IIb1, IIb2, IIb3, and IIc.

[0185] The binding sites on human and mouse antibodies for FcγR have previously been determined to be residues G233 to S239 (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), Woof et al., Molec. Immunol. 23:319-330 (1986); Duncan et al., Nature 332:563 (1988); Canfield and Morrison, J. Exp. Med. 173:1483-1491 (1991); Chappel et al., Proc. Natl. Acad. Sci USA 88:9036-9040 (1991)) (EU index numbering as in). Of the residues G233-S239, P238 and S239 have been cited as possibly involved in binding. Other residues involved in binding to FcγR are G316-K338 (Woof et al., Mol. Immunol., 23:319-330 (1986)), K274-R301 (Sarmay et al., Molec. Immunol. 21:43-51 (1984)), Y407-R416 (Gergely et al., Biochem. Soc. Trans. 12:739-743 (1984) and Shields et al., J Biol Chem 276:6591-6604 (2001), Lazar GA et al., Proc Natl Acad Sci 103:4005-4010(2006)), N297, T299, E318, L234-S239, N265-E269, N297-T299, and A327-I332. These and other stretches or regions of amino acid residues involved in FcR binding will be apparent to one of skill in the art from examination of the crystal structure of an Ig-FcR complex (see, for example, Sondermann et al. 2000 Nature 406(6793):267-73 and Sondermann et al. 2002 Biochem Soc Trans. 30(4):481-6). Thus, the anti-integrin antibodies of the invention include modifications of one or more of the above-mentioned residues to reduce effector function, as appropriate.

[0186] Another approach to modifying the effector function of monoclonal antibodies involves mutating amino acids on the surface of the monoclonal antibody that are involved in effector binding interactions (Lund, J., et al. (1991) J. Immunol. 147(8):2657-62; Shields, R Let al. (2001) J. Biol. Chem. 276(9):6591-604).

[0187] To reduce effector function, a combination of different subtype sequence segments (e.g., a combination of IgG2 and IgG4) can be used to reduce binding to Fcγ receptors to a greater extent than either subtype alone (Armour et al., Eur. J. Immunol., 29:2613-1624 (1999); Mol. Immunol., 40:585-593 (2003)). Numerous Fc variants with altered and / or reduced affinity for some or all Fc receptor subtypes (and thus for effector function) are known in the art. For example, US2007 / 0224188, US2007 / 0148171, US2007 / 0048300, US2007 / 0041966, US2007 / 0009523, US2007 / 0036799, US2006 / 0275283, US2006 / 0235208, US2006 / 0193856, US2006 / 0160996, See US2006 / 0134105, US2006 / 0024298, US2005 / 0244403, US2005 / 0233382, US2005 / 0215768, US2005 / 0118174, US2005 / 0054832, US2004 / 0228856, US2004 / 132101, US2003 / 158389. See also US 7,183,387, 6,737,056, 6,538,124, 6,528,624, 6,194,551, 5,624,821, 5,648,260, and Wang, X., Mathieu, M. & Brezski, RJ, Protein Cell, (2018) 9:63.doi.org / 10.1007 / s13238-017-0473-8. In certain embodiments, amino acids at positions 232, 234, 235, 236, 237, 239, 264, 265, 267, 269, 270, 299, 325, 328, 329, and 330 (numbered according to EU numbering) are substituted to reduce effector function.Non-limiting examples of substitutions that reduce effector function include one or more of K322A, L234A / L235A, G236T, G236R, G236Q, H268A, H268Q, V309L, A330S, P331S, V234A / G237A / P238S / H268A / V309L / A330S / P331S, E233P / L234V / L235A / G236Q+A327G / A330S / P331S, and L235E+E318A / K320A / K322A.

[0188] Antibodies of the invention with reduced effector function include antibodies that have reduced binding affinity to one or more Fc receptors (FcRs) compared to the parent or non-variant antibody. Thus, antibodies described herein with reduced FcR binding affinity include antibodies that have a 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 25-fold or greater reduction in binding affinity to one or more Fc receptors compared to the parent or non-variant antibody. In some embodiments, any of the antibodies described herein with reduced effector function binds to FcR with about 10-fold lower affinity compared to the parent or non-variant antibody. In other embodiments, any of the antibodies described herein with reduced effector function binds to FcR with about 15-fold lower affinity or about 20-fold lower affinity compared to the parent or non-variant antibody. The FcR receptor may be one or more of FcγRI (CD64), FcγRII (CD32), and FcγRIII and their isoforms, as well as FcεR, FcμR, FcδR, and / or FcαR. In certain embodiments, any of the antibodies described herein with reduced effector function has a 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, or 5-fold or greater decrease in binding affinity for FcγRIIa.

[0189] In CDC, antibody-antigen complexes bind complement, leading to the activation of the complement cascade and the generation of membrane attack complexes. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to an antibody (of the appropriate subclass) that is bound to its cognate antigen, and thus activation of the complement cascade is regulated, in part, by the binding affinity of immunoglobulins to the C1q protein. To activate the complement cascade, C1q must bind to at least two molecules of IgG1, IgG2, or IgG3 bound to an antigen target, but only one molecule of IgM (Ward and Ghetie, Therapeutic Immunology 2:77-94 (1995) p.80). To assess complement activation, a CDC assay may be performed, for example, as described in Gazzano-Santoro et al., J. Immunol. Methods, 202:163 (1996).

[0190] Various residues in the IgG molecule have been proposed to be involved in binding to C1q, including Glu318, Lys320, and Lys322 residues on the CH2 domain, amino acid residue 331 located in a turn adjacent to the same β-strand, Lys235 and Gly237 residues located in the lower hinge region, and residues 231-238 located in the N-terminal region of the CH2 domain (see, e.g., Xu et al., J. Immunol. 150:152A(Abstract)(1993), WO94 / 29351; Tao et al., J. Exp. Med., 178:661-667(1993); Brekke et al., Eur. J. Immunol., 24:2542-47(1994); Burton et al., Nature, 288:338-344(1980); Duncan and Winter, Nature. 332:738-40 (1988); Idusogie et al J Immunol 164:4178-4184 (2000; see US 5,648,260 and US 5,624,821).

[0191] The antibodies described herein with reduced C1q binding can comprise amino acid substitutions at one, two, three or four of amino acid positions 270, 322, 329 and 331 of the human IgG Fc region, where the numbering of residues in the IgG Fc region is that of the EU index as per Kabat. As an example in IgG1, two mutations in the COOH-terminal region of the CH2 domain of human IgG1-K322A and P329A- were shown to not activate the CDC pathway and to result in a greater than 100-fold reduction in C1q binding (US 6,242,195).

[0192] Thus, in certain embodiments, an antibody of the present invention has reduced binding to complement proteins compared to a second antibody (exemplary antibodies 1-20 having a wild-type Fc region (e.g., IgG1, IgG2, IgG3, etc.)). In certain embodiments, an antibody of the present invention has reduced binding to C1q by about 1.5-fold or more, about 2-fold or more, about 3-fold or more, about 4-fold or more, about 5-fold or more, about 6-fold or more, about 7-fold or more, about 8-fold or more, about 9-fold or more, about 10-fold or more, or about 15-fold or more compared to the second antibody.

[0193] Thus, in certain embodiments of the invention, one or more of these residues may be modified, substituted or removed, or one or more amino acid residues may be inserted, thereby reducing the CDC activity of the antibodies provided herein.

[0194] In certain other embodiments, the invention provides antibodies that have reduced binding to one or more FcR receptors but maintain their ability to bind complement (e.g., to a similar extent as the native, non-variant, or parent antibody, or in some embodiments, to a lesser extent). Thus, the antibodies of the invention can bind and activate complement while having reduced binding to an FcR, such as, for example, FcγRIIa (e.g., FcγRIIa expressed on platelets). Such antibodies that have reduced or no binding to FcγRIIa (e.g., FcγRIIa expressed on platelets), but can bind C1q and activate the complement cascade at least to some extent, reduce the risk of thromboembolic events, perhaps while maintaining desired effector functions. In alternative embodiments, the antibodies of the invention have reduced binding to one or more FcRs but maintain the ability to bind to one or more other FcRs. See, e.g., US 2007-0009523, 2006-0194290, 2005-0233382, 2004-0228856, and 2004-0191244, which describe various amino acid modifications that generate antibodies with reduced binding to FcRI, FcRII, and / or FcRIII, as well as amino acid substitutions that result in increased binding to one FcR but reduced binding to another FcR.

[0195] Thus, the effector function associated with the constant region of the antibody described herein can be modulated by modifying the properties of the constant region, particularly the Fc region. In certain embodiments, an antibody with reduced effector function is compared to a second antibody with effector function, and the second antibody can be a non-variant antibody, a natural antibody, or a parent antibody that includes a native constant region or Fc region that mediates the effector function. In some cases, when the antibody is an anti-integrin (e.g., anti-αvβ1 Ab, anti-αvβ1 and anti-αvβ6 Ab, anti-αvβ1 and another RGD-binding integrin Ab) human IgG1 antibody with a modified Fc that reduces effector function, the second antibody is a wild-type human IgG1 antibody.

[0196] A native constant region comprises an amino acid sequence identical to that of a constant chain region found in nature. Preferably, the control molecule used to evaluate the relative effector function comprises an Fc region of the same type / subtype as the test or variant antibody. A variant or modified Fc or constant region comprises an amino acid sequence that differs from that of a native sequence heavy chain region by at least one amino acid modification (e.g., post-translational modification, amino acid substitution, insertion, or deletion, etc.). Thus, a variant constant region may contain one or more amino acid substitutions, deletions, or insertions that result in modified post-translational modifications, including, for example, modified glycosylation patterns. A variant constant region may have reduced effector function.

[0197] Antibodies with reduced effector function(s) can be generated by engineering or producing antibodies with variant constant regions, Fc regions, or heavy chain regions. Recombinant DNA technology and / or cell culture and expression conditions can be used to produce antibodies with altered function and / or activity. For example, recombinant DNA technology may be used to engineer one or more amino acid substitutions, deletions, or insertions in regions (such as, for example, Fc or constant regions) that affect antibody function, including effector function. Alternatively, changes in post-translational modifications, such as, for example, glycosylation patterns, can be achieved by manipulating the host cells and cell culture and expression conditions in which the antibodies are produced.

[0198] Certain embodiments of the present invention relate to antibodies that comprise or consist of the three heavy chain variable region and three light chain variable region CDR sequences (enhanced Chothia, Kabat, or any other CDR definitions) of exemplary antibodies 1-20, and further comprise an Fc region that confers reduced effector function compared to the native or parent Fc region (e.g., an IgG4 Fc region).

[0199] Methods for generating any of the above-mentioned antibody variants, including amino acid substitutions, are well known in the art. These methods include, but are not limited to, preparation by site-directed (or oligonucleotide-mediated) mutagenesis, PCR mutagenesis, and cassette mutagenesis of prepared DNA molecules encoding antibodies or at least the constant regions of the antibodies. Site-directed mutagenesis is well known in the art (see, for example, Carter et al., Nucleic Acids Res., 13:4431-4443 (1985) and Kunkel et al., Proc. Natl. Acad. Sci. USA, 82:488 (1987)). PCR mutagenesis is also suitable for generating amino acid sequence variants of a starting polypeptide. See Higuchi, in PCR Protocols, pp.177-183 (Academic Press, 1990), and Vallette et al., Nuc. Acids Res. 17:723-733 (1989). Another method for preparing sequence variants, cassette mutagenesis, is based on the technique described by Wells et al., Gene, 34:315-323 (1985).

[0200] Antibodies with modified glycosylation Different glycoforms can significantly affect therapeutic drug properties, including pharmacokinetics, pharmacodynamics, receptor interactions, and tissue-specific targeting (Graddis et al., 2002, Curr Pharm Biotechnol. 3:285-297). In particular, for antibodies, the oligosaccharide structure can affect properties related to protease resistance, serum half-life of antibodies mediated by the FcRn receptor, phagocytosis, and antibody feedback, in addition to antibody effector functions (e.g., binding to complement complex C1 to induce CDC, and binding to FcγR receptors responsible for regulating the ADCC pathway) (Nose and Wigzell, 1983; Leatherbarrow and Dwek, 1983; Leatherbarrow et al., 1985; Walker et al., 1989; Carter et al., 1992, PNAS, 89:4285-4289).

[0201] Therefore, another means of modulating the effector function of antibodies includes modifying the glycosylation of the antibody constant region. Modification of glycosylation includes, for example, reducing or increasing the number of glycosylated residues, changing the pattern or position of glycosylated residues, and changing the sugar structure(s). The oligosaccharides found on human IgG affect the extent of their effector function (Raju, TSBioProcess International April 2003.44-53). The microheterogeneity of human IgG oligosaccharides can affect biological functions such as CDC and ADCC, binding to various Fc receptors, and binding to Clq proteins (Wright A. & Morrison SL. TIBTECH 1997,15 26-32; Shields et al. J Biol Chem. 2001 276(9):6591-604; Shields et al. J Biol Chem. 2002;277(30):26733-40; Shinkawa et al. J Biol Chem. 2003 278(5):3466-73; Umana et al. Nat Biotechnol. 1999 Feb;17(2):176-80). For example, the ability of IgG to bind C1q and activate the complement cascade may depend on the presence, absence, or modification of a carbohydrate moiety located between the two CH2 domains (usually anchored at Asn297) (Ward and Ghetie, Therapeutic Immunology 2:77-94 (1995)).

[0202] Glycosylation sites within an Fc-containing polypeptide, such as an antibody, for example an IgG antibody, can be identified by standard techniques. Identification of glycosylation sites can be experimental or based on sequence analysis or modeling data. Consensus motifs, i.e., amino acid sequences recognized by various glycosyltransferases, have been described. For example, consensus motifs for N-linked glycosylation motifs are frequently NXT or NXS, where X may be any amino acid except proline. Several algorithms for locating potential glycosylation motifs have also been described. Thus, to identify potential glycosylation sites within an antibody or Fc-containing fragment, the sequence of the antibody is examined using publicly available databases, such as, for example, the website provided by the Center for Biological Sequence Analysis (see NetNGlyc service for predicting N-linked glycosylation sites and NetOGlyc service for predicting O-linked glycosylation sites).

[0203] In vivo studies have confirmed the reduced effector function of non-glycosylated antibodies: for example, non-glycosylated anti-CD8 antibodies fail to deplete CD8-bearing cells in mice (Isaacs, 1992 J. Immunol. 148:3062), and non-glycosylated anti-CD3 antibodies do not induce cytokine release syndrome in mice or humans (Boyd, 1995 supra; Friend, 1999 Transplantation 68:1632).

[0204] Importantly, removal of glycans within the CH2 domain appears to significantly affect effector function, while other functional and physical properties of the antibody remain unaltered. Specifically, it has been shown that removal of glycans had little or no effect on serum half-life and antigen binding (Nose, 1983 supra; Tao, 1989 supra; Dorai, 1991 supra; Hand, 1992 supra; Hobbs, 1992 Mol. Immunol. 29:949).

[0205] The antibodies of the present invention may be modified or altered to induce a reduction in effector function(s) compared to a second antibody (e.g., exemplary antibodies 1-20 having wild-type human IgG1, IgG2, IgG3 Fc regions). Methods for altering glycosylation sites of antibodies are described, for example, in US6,350,861 and US5,714,350, WO05 / 18572 and WO05 / 03175, and these methods can be used to produce antibodies of the present invention with altered, reduced, or no glycosylation.

[0206] In some cases, the antibodies of the disclosure include an Fc region (e.g., a human IgG1 Fc) with a modification that reduces or eliminates glycosylation in the Fc region (e.g., a T299A or N297Q substitution (numbering according to EU numbering)).

[0207] Alternatively, the antibodies of the invention can be produced in a cell line that provides the desired glycosylation profile. For example, cells that make little to no afucosylated antibodies, such as CHO cells, can be used for production.

[0208] In another embodiment, the manufacturing process and / or medium content or conditions may be manipulated to modulate the galactose and / or high mannose content. In one embodiment, the galactose / high mannose content of the antibody is low or reduced.

[0209] affinity maturation In one embodiment, the anti-integrin antibodies described herein are modified, e.g., by mutagenesis, to provide a pool of modified antibodies. The modified antibodies are then evaluated to identify one or more antibodies with altered functional properties (e.g., improved binding, improved stability, reduced antigenicity, or increased in vivo stability). In one embodiment, display library technology is used to select or screen the pool of modified antibodies. Higher affinity antibodies are then identified from the second library, e.g., by using higher stringency or more competitive binding and washing conditions. Other screening techniques can also be used.

[0210] In some embodiments, mutagenesis targets known or likely regions of the binding interface.For example, if the identified binding protein is an antibody, mutagenesis can be directed to the CDR regions of the heavy or light chain described herein.Furthermore, mutagenesis can be directed to framework regions near or adjacent to the CDRs, for example, framework regions within 10, 5, or 3 amino acids, particularly, of the CDR junction.In the case of antibodies, mutagenesis can also be limited to one or several of the CDRs, for example, to make stepwise improvements.

[0211] In one embodiment, mutagenesis is used to make the antibody more similar to one or more germline sequences. One exemplary germlining method can include identifying one or more germline sequences that are similar to the sequence of the isolated antibody (e.g., most similar in a particular database). Mutations (at the amino acid level) can then be made incrementally, combinatorially, or both within the isolated antibody. For example, a nucleic acid library is created that includes sequences that code for some or all possible germline mutations. The mutated antibodies are then evaluated to identify antibodies that, for example, have one or more additional germline residues compared to the isolated antibody and are still useful (e.g., have functional activity). In one embodiment, as many germline residues as possible are introduced into the isolated antibody.

[0212] In one embodiment, mutagenesis is used to replace or insert one or more germline residues into the CDR region. For example, the germline CDR residues can be derived from a germline sequence that is similar (e.g., most similar) to the variable region to be modified. After mutagenesis, the activity (e.g., binding or other functional activity) of the antibody can be evaluated to determine whether one or more germline residues are tolerated. Similar mutagenesis can be performed in the framework regions.

[0213] Selection of germline sequences can be performed in different ways. For example, a germline sequence can be selected if it meets a predefined criterion for selectivity or similarity, e.g., at least a certain percentage of identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity) compared to the donor non-human antibody. Selection can be performed using at least 2, 3, 5, or 10 germline sequences. In the case of CDR1 and CDR2, identifying a similar germline sequence can include selecting one such sequence. In the case of CDR3, identifying a similar germline sequence can include selecting one such sequence, but can also include using two germline sequences that contribute separately to the amino-terminal and carboxy-terminal portions. In other embodiments, for example, more than one or two germline sequences are used to form a consensus sequence.

[0214] Calculation of "sequence identity" between two sequences is performed as follows: The sequences are aligned for optimal comparison (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison). Optimal alignment is determined as the best score using the GAP program of the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between two sequences is a function of the number of identical positions shared by the sequences.

[0215] In other embodiments, an antibody may be modified to have an altered glycosylation pattern (i.e., altered from the original or native glycosylation pattern). As used in this context, "altered" means that one or more carbohydrate moieties have been deleted and / or one or more glycosylation sites have been added to the original antibody. Addition of glycosylation sites to the antibodies of the present disclosure may be accomplished by modifying the amino acid sequence to contain a consensus sequence for a glycosylation site, and such techniques are well known in the art. Another means of increasing the number of carbohydrate moieties on an antibody is by chemical or enzymatic coupling of glycosides to amino acid residues of the antibody. These methods are described, for example, in WO87 / 05330, and in Aplin and Wriston (1981) CRC Crit. Rev. Biochem., 22:259-306. Removal of any carbohydrate moieties present on the antibody may be accomplished chemically or enzymatically as described in the art (Hakimuddin et al. (1987) Arch. Biochem. Biophys., 259:52; Edge et al. (1981) Anal. Biochem., 118:131; and Thotakura et al. (1989) Anal. Biochem., 118:132). (Et al. (1987) Meth. Enzymol., 138:350). For modifications that increase in vivo half-life by providing salvage receptor binding epitopes, see, e.g., U.S. Patent No. 5,869,046.

[0216] Unlike CDRs, more substantial changes in the structural framework regions (FRs) can be made without adversely affecting the binding properties of the antibody. Changes to FRs include, but are not limited to, humanizing frameworks of non-human origin, or manipulating specific framework residues that are important for antigen contact or for stabilizing the binding site, for example, changing the class or subclass of the constant region, changing specific amino acid residues that can modify effector functions such as Fc receptor binding (Lund et al., J. Immun., 147:2657-62 (1991); Morgan et al., Immunology, 86:319-24 (1995)), or changing the species from which the constant region is derived.

[0217] The anti-integrin antibody may be in the form of a full-length (or whole) antibody, such as Fab, Fab', F(ab')2, Fv, Fd, dAb, scFv, and sc(Fv)2, or in the form of a low molecular weight form thereof (e.g., biologically active antibody fragment or minibody). Other anti-integrin antibodies encompassed by the present disclosure include single domain antibodies (sdAbs) that contain a single variable chain, such as VH or VL, or a biologically active fragment thereof. See, for example, Moller et al., J. Biol. Chem., 285(49):38348-38361(2010); Harmsen et al., Appl. Microbiol. Biotechnol., 77(1):13-22(2007); US2005 / 0079574 and Davies ... See, al. (1996) Protein Eng., 9(6):531-7. Like whole antibodies, sdAbs can selectively bind to specific antigens (e.g., αvβ1, αvβ1, and αvβ6). With a molecular weight of only 12-15 kDa, sdAbs are much smaller than typical antibodies, even smaller than Fab fragments and single chain variable fragments.

[0218] In certain embodiments, the anti-integrin antibody or antigen-binding fragment thereof, or low molecular weight antibody thereof, specifically binds to αvβ1 or αvβ1 and αvβ6, and reduces the severity of symptoms when administered to a human patient with one or more of fibrosis (e.g., liver fibrosis, pulmonary fibrosis, renal fibrosis), acute lung injury, or acute kidney injury, or to an animal model of fibrosis (e.g., liver fibrosis, pulmonary fibrosis, renal fibrosis), acute lung injury, or acute kidney injury. In one embodiment, the anti-integrin antibody or low molecular weight antibody thereof inhibits disease development in an idiopathic pulmonary fibrosis model (Degryse et al., Am J Med Sci., 341(6):444-9(2011)). These characteristics of the anti-integrin antibody or low molecular weight antibody thereof can be measured according to methods known in the art.

[0219] Nucleic acids, vectors and host cells The present disclosure also features nucleic acids encoding the antibodies disclosed herein. Provided herein are nucleic acids encoding the VH CDR1, VH CDR2, and VH CDR3 of the anti-integrin antibodies described herein (e.g., exemplary antibodies 1-20). Also featured are nucleic acids encoding the VL CDR1, VL CDR2, and VL CDR3 of the anti-integrin antibodies described herein (e.g., exemplary antibodies 1-20). Provided herein are nucleic acids encoding the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the anti-integrin antibodies described herein (e.g., exemplary antibodies 1-20). Also provided herein are nucleic acids encoding the heavy chain variable region (VH) of the anti-integrin antibodies described herein (e.g., exemplary antibodies 1-20) and / or the light chain variable region (VL) of the anti-integrin antibodies described herein (e.g., exemplary antibodies 1-20). In certain cases, provided herein are nucleic acids encoding the VH and / or VL of an anti-integrin antibody described herein (e.g., Exemplary Antibodies 1-20) linked to a human heavy chain and / or human light chain constant region, respectively. Also provided herein are nucleic acids encoding both the VH and VL of an anti-integrin antibody described herein (e.g., Exemplary Antibodies 1-20). In some cases, the nucleic acids described herein include nucleic acids encoding an Fc region of a human antibody (e.g., human IgG1, IgG2, IgG3, or IgG4). In certain cases, the nucleic acids include nucleic acids encoding an Fc region of a human antibody that has been modified to reduce or eliminate effector function (e.g., an N297Q or T299A substitution (numbering according to EU numbering) in a human IgG1 Fc region). Optionally, the nucleic acid comprises a nucleic acid encoding an Fc portion that is hIgG1 Fc, hIgG2 Fc, hIgG3 Fc, hIgG4 Fc, hIgG1agly Fc, hIgG2 SAA Fc, hIgG4(S228P) Fc, or hIgG4(S228P) / G1 agly Fc.

[0220] Also disclosed herein are vectors (eg, expression vectors) that contain any of the above-described nucleic acids.

[0221] Furthermore, the present disclosure relates to host cells (e.g., bacterial, yeast, insect, or mammalian cells) containing the above-mentioned vector(s) or nucleic acid(s).

[0222] Methods for Producing Anti-Integrin Antibodies Antibodies such as those described above can be made, for example, by preparing and expressing synthetic genes encoding the recited amino acid sequences. Methods for generating variants (e.g., including amino acid substitutions) of any of the anti-integrin antibodies are well known in the art. These methods include, but are not limited to, preparation by site-directed (or oligonucleotide-mediated) mutagenesis, PCR mutagenesis, and cassette mutagenesis of prepared DNA molecules encoding the antibody or any portion thereof (e.g., framework regions, CDRs, constant regions). Site-directed mutagenesis is well known in the art (see, for example, Carter et al., Nucleic Acids Res., 13:4431-4443 (1985) and Kunkel et al., Proc. Natl. Acad. Sci. USA, 82:488 (1987)). PCR mutagenesis is also suitable for making amino acid sequence variants of a starting polypeptide. See Higuchi, in PCR Protocols, pp. 177-183 (Academic Press, 1990), and Vallette et al., Nuc. Acids Res. 17:723-733 (1989). Another method for preparing sequence variants, cassette mutagenesis, is based on the technique described by Wells et al., Gene, 34:315-323 (1985).

[0223] Antibodies or antigen-binding fragments thereof can be produced in bacterial or eukaryotic cells. Some antibodies, e.g., Fabs, can be produced in bacterial cells, e.g., E. coli cells. Antibodies or antigen-binding fragments thereof can also be produced in eukaryotic cells, such as transformed cell lines (e.g., CHO, 293E, COS, Hela). In addition, antibodies (e.g., scFvs) can be produced in eukaryotic cells, such as Pichia (see, e.g., Powers et al., J Immunol Methods. 251:123-35 (2001)), Hanseula, or Saccharomyces. In one embodiment, the antibodies described herein are produced in the dihydrofolate reductase-deficient Chinese hamster ovary (CHO) cell line DG44. In another embodiment, the antibodies described herein are produced in the DG44i cell line. To produce an antibody of interest or an antigen-binding fragment thereof, a polynucleotide encoding the antibody is constructed, introduced into an expression vector, and then expressed in a suitable host cell. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells, and recover the antibody.

[0224] When the antibody is expressed in bacterial cells (e.g., E. coli), the expression vector should have characteristics that allow the amplification of the vector in the bacterial cell. Furthermore, when E. coli such as JM109, DH5α, HB101, or XL1-Blue is used as the host, the vector must have a promoter, such as the lacZ promoter (Ward et al., 341:544-546 (1989)), the araB promoter (Better et al., Science, 240:1041-1043 (1988)), or the T7 promoter that can allow efficient expression in E. coli. Examples of such vectors include, for example, M13 series vectors, pUC series vectors, pBR322, pBluescript, pCR-Script, pGEX-5X-1 (Pharmacia), "QIAexpress system" (QIAGEN), pEGFP, and pET (when this expression vector is used, the host is preferably BL21, which expresses T7 RNA polymerase). The expression vector may contain a signal sequence for antibody secretion. For production into the periplasm of E. coli, the pelB signal sequence (Lei et al., J. Bacteriol., 169:4379 (1987)) may be used as the signal sequence for antibody secretion. For bacterial expression, the calcium chloride method or electroporation method may be used to introduce the expression vector into bacterial cells.

[0225] When the antibody is expressed in animal cells such as CHO, COS, and NIH3T3 cells, the expression vector contains a promoter necessary for expression in these cells, such as the SV40 promoter (Mulligan et al., Nature, 277:108 (1979)), the MMLV-LTR promoter, the EF1α promoter (Mizushima et al., Nucleic Acids Res., 18:5322 (1990)), or the CMV promoter. In addition to the nucleic acid sequence encoding an immunoglobulin or a domain thereof, the recombinant expression vector may carry additional sequences such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see, e.g., U.S. Pat. Nos. 4,399,216, 4,634,665, and 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector is introduced. Examples of vectors having selectable markers include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.

[0226] In one embodiment, the antibody is produced in a mammalian cell. Exemplary mammalian host cells for expressing the antibody include Chinese Hamster Ovary (CHO) cells (dhfr-CHO cells, as described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220). - These include CHO cells, e.g., used with the DHFR selection marker as described in Kaufman and Sharp (1982) Mol. Biol. 159:601-621), human embryonic kidney 293 cells (e.g., 293, 293E, 293T), COS cells, NIH3T3 cells, lymphoid cell lines, e.g., NS0 myeloma cells and SP2 cells, and cells derived from transgenic animals, e.g., transgenic mammals. For example, the cell is a mammary epithelial cell.

[0227] In an exemplary system for antibody expression, recombinant expression vectors encoding the antibody heavy chain and the antibody light chain, respectively, of any antibody described herein (e.g., exemplary antibodies 1-20) are transfected into the dhfr vector by calcium phosphate-mediated transfection. - In a particular embodiment, the dhfr gene is introduced into a CHO cell. - The CHO cells are cells of the DG44 cell line, such as DG44i (see, e.g., Derouaz et al., Biochem Biophys Res Commun. 340(4):1069-77 (2006)). Within the recombinant expression vector, the antibody heavy and light chain genes are each operably linked to enhancer / promoter regulatory elements (e.g., derived from SV40, CMV, adenovirus, etc., such as the CMV enhancer / AdMLP promoter regulatory element or the SV40 enhancer / AdMLP promoter regulatory element) to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for the selection of CHO cells transfected with the vector using methotrexate selection / amplification. The selected transformant host cells are cultured to allow expression of the antibody heavy and light chains, and the antibody is recovered from the culture medium.

[0228] Antibodies can also be produced by transgenic animals. For example, US Patent No. 5,849,992 describes a method for expressing antibodies in the mammary gland of a transgenic mammal. A transgene is constructed that includes a milk-specific promoter and a nucleic acid that encodes the antibody of interest and a signal sequence for secretion. The milk produced by the female of such a transgenic mammal contains the antibody of interest secreted therein. The antibody can be purified from the milk or, for some applications, can be used directly. Also provided are animals that include one or more of the nucleic acids described herein.

[0229] The antibodies of the present disclosure can be isolated from the inside or outside (such as the medium) of the host cells and purified as a substantially pure and homogeneous antibody. Isolation and purification methods commonly used for antibody purification may be used for antibody isolation and purification, and are not limited to any particular method. Antibodies can be isolated and purified by appropriately selecting and combining, for example, column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, and recrystallization. Chromatography includes, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reversed-phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Manual). Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). Chromatography can be performed using liquid phase chromatography such as HPLC and FPLC. Columns used for affinity chromatography include Protein A and Protein G columns. Examples of columns using Protein A columns include Hyper D, POROS, and Sepharose FF (GE Healthcare Biosciences). The present disclosure also includes antibodies that are highly purified using these purification methods.

[0230] Antibody characterization The integrin binding properties of the antibodies described herein can be measured by any standard method, for example, one or more of the following methods: OCTET (registered trademark), surface plasmon resonance (SPR), BIACORE (trademark) analysis, enzyme-linked immunosorbent assay (ELISA), EIA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), and fluorescence resonance energy transfer (FRET).

[0231] The binding interaction between a protein of interest (anti-integrin antibody) and a target (e.g., integrin) can be analyzed using the OCTET® system. In this method, several variations of the instrument made by ForteBio (e.g., OCTET® QK e and QK) to determine protein interactions, binding specificity, and epitope mapping. The OCTET® system can easily monitor real-time binding by measuring the change in polarized light that travels down a custom chip and back to the sensor.

[0232] Binding interactions between a protein of interest (anti-integrin antibody) and a target (e.g., integrin) can be analyzed using surface plasmon resonance (SPR). SPR, or biomolecular interaction analysis (BIA), detects bispecific interactions in real time, without labeling any of the interactants. A change in mass at the binding surface of the BIA chip (indicative of a binding event) results in a change in the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)). The change in refractive index generates a detectable signal that is measured as an indication of real-time reactions between biomolecules. Methods using SPR are described, for example, in U.S. Patent No. 5,641,640, Raether (1988) Surface Plasmons Springer Verlag; Sjolander and Urbaniczky (1991) Anal. Chem. 63:2338-2345; Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699-705, and an online resource provided by BIAcore International AB (Uppsala, Sweden). Information from SPR can be used to determine the equilibrium dissociation constant (K d ), and K on and K off The present invention can be used to provide accurate and quantitative measurements of kinetic parameters, including

[0233] Epitopes can also be directly mapped by assessing the ability of different antibodies to compete with each other for binding to one or more RGD-binding integrins selected from the group consisting of human αvβ1, αvβ6, or αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3 using BIACORE chromatography technology (Pharmacia BIAtechnology Handbook, "Epitope "Mapping", Section 6.3.2, (May 1994); see also Johne et al. (1993) J. Immunol. Methods, 160:191-198).

[0234] When using an enzyme immunoassay, a sample containing an antibody, for example, a culture supernatant of antibody-producing cells or a purified antibody, is added to an antigen-coated plate. A secondary antibody labeled with an enzyme such as alkaline phosphatase is added, the plate is incubated, washed, and then an enzyme substrate such as p-nitrophenyl phosphate is added, and the antigen-binding activity is evaluated by measuring the absorbance.

[0235] Further general guidance for evaluating antibodies, e.g., Western blot and immunoprecipitation assays can be found in Antibodies: A Laboratory Manual, ed. by Harlow and Lane, Cold Spring Harbor press (1988).

[0236] Indications A. Group I-III antibodies αvβ1 integrin is highly expressed on activated fibroblasts and plays a role in activating transforming growth factor β (TGFβ) and promoting tissue fibrosis (Reed et al. Sci, Transl. Med., 7:288 (2015)). Thus, any of the antibodies described herein (e.g., Group I, II and III antibodies) can be used to treat or prevent any fibrotic disease or condition described herein or known in the art. In some embodiments, the antibodies described herein block at least the activation of TGFβ and are therefore useful for treating or preventing such diseases or conditions.

[0237] The antibodies provided herein can be used to treat or prevent organ fibrosis, soft tissue fibrosis, joint and connective tissue fibrosis, and multi-organ or systemic fibrosis. Non-limiting examples of organ fibrosis include pulmonary fibrosis, renal fibrosis, liver / hepatic fibrosis, head and neck fibrosis, spinal cord injury / fibrosis, glial scarring in the brain, ocular fibrosis, cardiac fibrosis, skin fibrosis, and bone marrow fibrosis. Non-limiting examples of soft tissue fibrosis include mediastinal fibrosis and retroperitoneal fibrosis. Non-limiting examples of joint and connective tissue fibrosis include arthrofibrosis and adhesive capsulitis. Non-limiting examples of multi-organ or systemic fibrosis include sarcoidosis, systemic sclerosis, amyloidosis, surgical fibrosis, and nephrogenic systemic fibrosis.

[0238] The antibodies provided herein can be used to treat or prevent pulmonary fibrosis, such as, but not limited to, IPF (idiopathic pulmonary fibrosis), acute exacerbation of IPF, radiation-induced lung injury / fibrosis, influenza-induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, common interstitial pneumonia (UIP), chronic obstructive pulmonary disease (COPD), bleomycin-induced fibrosis, asthma (e.g., chronic asthma), silicosis, asbestos-induced fibrosis, acute lung injury, and acute respiratory distress (including bacterial pneumonia-induced, trauma-induced, viral pneumonia-induced, ventilator-induced, non-pulmonary sepsis-induced, and aspiration-induced), pulmonary histiocytosis X, and progressive massive fibrosis.

[0239] The antibodies provided herein can be used to treat or prevent renal fibrosis, including, but not limited to, acute kidney injury, idiopathic renal syndromes, idiopathic membranoproliferative glomerulonephritis, chronic nephropathies associated with injury and / or fibrosis (e.g., lupus, diabetes, scleroderma, glomerulonephritis, focal segmental glomerulosclerosis, IgA nephropathy, hypertension, allografts, and Alport's disease).

[0240] The antibodies provided herein can be used to treat or prevent liver / hepatic fibrosis (such as, but not limited to, acute liver injury, bile duct injury-induced fibrosis, and cirrhosis), intestinal fibrosis (such as, but not limited to, inflammatory bowel disease and Crohn's disease), ocular fibrosis (such as, but not limited to, corneal scarring, LASIX, corneal transplantation, and trabeculectomy), cardiac fibrosis (such as, but not limited to, idiopathic restrictive cardiomyopathy, atrial fibrosis, endocardial fibrosis, and myocardial infarction), skin fibrosis (such as, but not limited to, hypertrophic scarring, ablative fibrosis, psoriasis, and keloids), and bone marrow fibrosis (such as, but not limited to, myelofibrosis).

[0241] The antibodies provided herein can be used to treat or prevent fatty liver disease and non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH).

[0242] B. Group II Antibodies The αvβ6 integrin can bind several ligands, including fibronectin, tenascin, and latency-associated peptide-1 and -3 (LAP1 and LAP3) (the N-terminal 278 amino acids of the latent precursor form of TGF-β1). TGF-β cytokines are synthesized as latent complexes in which the N-terminal LAP is non-covalently associated with the mature active C-terminal TGF-β cytokine. The latent TGF-β complex cannot bind to its cognate receptor and is therefore not biologically active until converted to the active form. αvβ6 binds to LAP1 and LAP3 through interactions with an arginine-glycine-aspartic acid ("RGD") motif, and this binding of αvβ6 to LAP1 or LAP3 activates the latent precursor forms of TGF-β1 and TGF-β3 as a result of a conformational change in the latent complex that allows TGF-β to bind to its receptor. Thus, upregulated expression of αvβ6 can lead to local activation of TGF-β, which can then activate a cascade of downstream events.

[0243] TGF-β cytokines are pleiotropic growth factors that regulate cell proliferation, differentiation, and immune responses. TGF-β also plays a role in cancer. Although TGF-β is recognized to have tumor suppressor and antiproliferative activity, many tumors evolve resistance to the antiproliferative activity of TGF-β. In established tumors, TGF-β expression and activity are involved in promoting tumor survival, progression, and metastasis. This is thought to be mediated by both autocrine and paracrine actions in the local tumor stromal environment, including the effects of TGF-β on immune surveillance, angiogenesis, and increased tumor interstitial pressure. Several studies have shown antitumor and antimetastatic effects by inhibiting TGF-β.

[0244] αvβ6 integrin is expressed on epithelial cells at relatively low levels in healthy tissues and is significantly upregulated during development, injury, and wound healing. αvβ6 integrin expression is upregulated in cancers of epithelial origin, including colon, squamous cell, ovarian, and breast cancers.

[0245] Antibodies described herein that bind to both αvβ1 and αvβ6 integrins but not other integrins (i.e., Group II antibodies) can be used to protect against epithelial and / or endothelial cell injury (e.g., alveolar epithelial injury). Group II antibodies described herein can be used to block the interaction of the αvβ6 receptor with RGD-containing ligands, such as proteins on the surface of viruses, thereby reducing or preventing viral infection.

[0246] The Group II antibodies described herein can be used to treat cancers or cancer metastasis (including tumor growth and invasion), such as, but not limited to, epithelial cancers. Non-limiting examples of epithelial cancers include squamous cell carcinomas, such as head and neck (including oral, laryngeal, pharyngeal, esophageal), breast, lung, prostate, cervical, colon, pancreas, skin (basal cell carcinoma), ovarian, and kidney cancers (e.g., renal cell carcinoma). The Group II antibodies described herein can also be used for brain and central nervous system tumors (e.g., glioblastoma), eye diseases (e.g., macular degeneration and age-related macular degeneration), osteoporosis, and kidney diseases, such as, but not limited to, chronic tubular disorders, chronic kidney disease, (chronic) interstitial fibrosis, tubular atrophy, and chronic allograft dysfunction in kidney transplant patients.

[0247] The present disclosure includes methods of treating or preventing metastatic cancer by identifying pre-invasive lesions or carcinomas in a patient and treating the patient to eliminate the pre-invasive lesions before they have an opportunity to evolve into invasive forms. Such methods include, for example, (a) obtaining a tissue sample suspected of containing cancer or a preinvasive lesion, and a tissue sample not containing cancer or a preinvasive lesion (preferably from the same tissue or organ as the tissue or organ suspected of containing cancer or a preinvasive lesion); (b) contacting the tissue sample with one or more αvβ6-binding ligands, such as any of the Group II antibodies described herein, under conditions that favor binding of the one or more αvβ6-binding ligands to αvβ6 integrin in the tissue, whenever present; and (c) detecting the level or pattern of binding of the αvβ6-binding ligand(s) to the tissue, wherein an increase in localized binding of an αvβ6-binding ligand in the myoepithelium surrounding a hyperplasia (e.g., a tumor) compared to binding in the hyperplasia itself (or cells thereof), or an increase in the binding level of an αvβ6-binding ligand in a tissue sample containing a cancerous or preinvasive lesion compared to binding in a non-cancerous tissue sample (or cells thereof) is indicative of a carcinoma that is likely to become invasive and metastasize. In other related embodiments, the present invention contemplates a method of reducing or preventing the progression of a pre-metastatic or pre-invasive tumor to a metastatic or invasive tumor in a patient, comprising administering to the patient a therapeutically effective amount of one or more ligands that bind to one or more subunits of integrin αvβ6 on one or more cells within the pre-metastatic or pre-invasive tumor, where binding of the ligand to the integrin reduces or prevents the infiltration of cells of the pre-metastatic or pre-invasive cancer into tissue regions surrounding the primary tumor. In other embodiments, the methods of the present invention are suitable for eliminating residual tumor cells, e.g., residual metastatic cells, after removal, treatment, or eradication of a tumor by a different approach. For example, such methods can be used to eliminate residual tumor cells or metastatic cells that may remain in a patient after surgical removal of the tumor or eradication of the tumor by methods such as irradiation, chemotherapy, etc. In such a treatment regimen, the methods of the present invention can include administering to the patient an αvβ6 binding antibody before, during, and / or after surgical, radiological, and / or chemotherapeutic ablation of the tumor.

[0248] C. Group III Antibodies The antibodies described herein that bind to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3 (i.e., Group III antibodies) can be used to treat cancer or cancer metastasis, such as, but not limited to, solid tumors (e.g., pancreatic or breast cancer). The Group III antibodies described herein can be used to treat ovarian, colorectal, and prostate cancer, with or without bone metastasis, as well as renal cell carcinoma, peritoneal cancer, brain and central nervous system tumors, and melanoma. The Group III antibodies described herein can be used to treat ophthalmic diseases, such as, but not limited to, macular degeneration, age-related macular degeneration (AMD), wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Group III antibodies described herein can also be used to treat acute coronary syndromes (ACS), autoimmune diseases, and osteoporosis. Non-limiting examples of autoimmune diseases include rheumatoid arthritis, psoriasis, lupus, inflammatory bowel disease, multiple sclerosis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, and vasculitis. The Group III antibodies described herein may be useful as antithrombotic agents and may be used, for example, during percutaneous coronary intervention (angioplasty with or without stent placement).

[0249] The efficacy of the antibodies of the invention can be evaluated in various animal models, including mouse models of pulmonary fibrosis, such as bleomycin (Pittet et al., J. Clin. Invest., 107(12):1537-1544 (2001), and Munger et al., Cell, 96:319-328 (1999)) and radiation-induced pulmonary fibrosis (Franko et al., Rad. Res., 140:347-355 (1994)). Mouse models of renal fibrosis include COL4A3− / − mice (see, e.g., Cosgrove et al., Amer. J. Path., 157:1649-1659 (2000)), mice with adriamycin-induced injury (Wang et al., Kidney International, 58:1797-1804 (2000); Deman et al., Nephrol Dial Transplant, 16:147-150 (2001)), db / db mice (Ziyadeh et al., Proc. Natl. Acad. Sci. USA, 97:8015-8020 (2000)), and mice with unilateral ureteral obstruction (Fogo et al., Lab Investigation, 81:189A (2001); and Fogo et al., Journal of the American Society of Nephrology, 12:819 (2001)). A (2001)). The αvβ6 antibodies described herein can be evaluated for their ability to inhibit tumor growth, progression, and metastasis in standard in vivo tumor growth and metastasis models. See, e.g., Rockwell et al., J. Natl. Cancer Inst., 49:735 (1972); Guy et al., Mol. Cell Biol., 12:954 (1992); Wyckoff et al., Cancer Res., 60:2504 (2000); and Oft et al., Curr. Biol., 8:1243 (1998).

[0250] The effectiveness of treatment can be measured by many available diagnostic tools, including physical examination, blood tests, proteinuria measurement, creatinine levels and creatinine clearance, pulmonary function tests, plasma blood urea nitrogen (BUN) levels, observation and scoring of scar or fibrotic lesions, deposition of extracellular matrix such as collagen, smooth muscle actin and fibronectin, renal function tests, ultrasound, magnetic resonance imaging (MRI), and CT scans.

[0251] Pharmaceutical Compositions The anti-integrin antibodies described herein can be formulated as pharmaceutical compositions for administration to a subject, for example, to treat a disease or condition described herein. Typically, a pharmaceutical composition includes a pharma- ceutically acceptable carrier. As used herein, a "pharma-ceutically acceptable carrier" includes any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are physiologically compatible. The compositions can include pharma-ceutically acceptable salts, such as acid or base addition salts (see, for example, Berge, SM, et al. (1977) J. Pharm. Sci. 66:1-19).

[0252] Pharmaceutical formulation is a well-established technique, see, for example, Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20 th ed., Lippincott, Williams & Wilkins (2000) (ISBN:0683306472), Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7 th Ed., Lippincott Williams & Wilkins Publishers (1999) (ISBN:0683305727), and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3 rded.(2000)(ISBN:091733096X).

[0253] Pharmaceutical compositions may be in various forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form may depend on the intended mode of administration and therapeutic application. Typically, the compositions for the agents described herein are in the form of injectable or infusible solutions.

[0254] Such compositions may be administered by a parenteral mode (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection). In one embodiment, the antibody compositions are administered intravenously. In another embodiment, the antibody compositions are administered subcutaneously. As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0255] The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable for stable storage at high concentration. Injectable sterile solution can be prepared by mixing the required amount of the agent described herein with a suitable solvent containing one or a combination of ingredients listed above, as needed, and then sterilizing by filtration. Generally, dispersion is prepared by mixing the agent described herein with a sterile vehicle containing a basic dispersion medium and other required ingredients listed above. In the case of sterile powder for preparing injectable sterile solution, the preferred preparation method is vacuum drying and freeze-drying, which brings the powder of the agent described herein plus any additional desired ingredients from the solution that has been previously sterile-filtered.

[0256] Administration The antibodies described herein can be administered to a subject, e.g., a human subject, in need of administration of the antibody, for example, by various methods. In many applications, the route of administration is one of intravenous injection or infusion (IV), subcutaneous injection (SC), intraperitoneal injection (IP), or intramuscular injection. Intra-articular delivery can also be used. Other modes of parenteral administration can also be used. Examples of such modes include intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, intra-articular, subcapsular, subarachnoid, intraspinal, as well as epidural and intrasternal injection. In some cases, administration can be oral.

[0257] The route and / or mode of administration of the antibody or antigen-binding fragment thereof can also be tailored to individual cases, e.g., by monitoring the subject using, e.g., tomographic imaging, to visualize the tumor.

[0258] If a subject is at risk of developing a disease or condition described herein, the antibody can be administered before the disease or condition fully develops, e.g., as a preventative measure. The duration of such preventative treatment can be a single dose of antibody, or the treatment can be continuous (e.g., multiple doses). For example, a subject at risk of a disease or a subject with a predisposition to a disease can be treated with an antibody for days, weeks, months, or years to prevent the onset or development of the disease.

[0259] A pharmaceutical composition may contain a "therapeutically effective amount" of an agent described herein. Such an effective amount may be determined based on the effect of the agent administered, or the combined effect of the agents when two or more agents are used. The therapeutically effective amount of an agent may also vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual, such as alleviation of at least one disease or condition parameter, or alleviation of at least one symptom of a disease or condition. A therapeutically effective amount is also one in which any toxic or adverse effects of the composition are outweighed by the therapeutically beneficial effects.

[0260] Therapeutic devices and kits Pharmaceutical compositions comprising the antibodies described herein can be administered using a medical device. The device can be designed with features such as portability, room temperature storage, and ease of use, and can be removed from medical facilities and other medical equipment for use in emergency situations, for example, by untrained subjects or by on-site emergency personnel. The device can include, for example, one or more housings for storing pharmaceutical preparations comprising the antibody, and can be configured to deliver one or more unit doses of the antibody. The device can be further configured to administer a second agent, either as a single pharmaceutical composition also comprising the antibody described herein, or as two separate pharmaceutical compositions.

[0261] The pharmaceutical composition can be administered using a syringe.The pharmaceutical composition can also be administered using a needleless hypodermic injection device, such as the devices disclosed in US5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824 or 4,596,556. Examples of known implants and modules include US 4,487,603, which discloses an implantable microinfusion pump for dispensing drugs at a controlled rate, US 4,486,194, which discloses a therapeutic device for administering drugs through the skin, US 4,447,233, which discloses a drug infusion pump for delivering drugs at a precise infusion rate, US 4,447,224, which discloses a variable flow rate implantable infusion device for continuous drug delivery, US 4,439,196, which discloses an osmotic drug delivery system with a multi-chamber compartment, and US 4,475,196, which discloses an osmotic drug delivery system. Many other devices, implants, delivery systems, and modules are also known.

[0262] The antibodies described herein can be provided in a kit. In one embodiment, the kit comprises (a) a container that holds a composition comprising an antibody described herein, and, optionally, (b) informational material. The informational material can be descriptive, instructional, marketing, or other material relating to the methods described herein and / or the use of the agents for therapeutic benefit.

[0263] In one embodiment, the kit also includes a second agent for treating a disease or condition described herein. For example, the kit includes a first container that holds a composition comprising an antibody described herein, and a second container that includes the second agent.

[0264] The informational material of the kit is not limited in its form. In one embodiment, the informational material can include information about the production of the compound, the molecular weight of the compound, concentration, expiration date, batch or site of production information, etc. In one embodiment, the informational material relates to methods of administering an antibody described herein, e.g., in a suitable mode of administration (e.g., a mode of administration described herein), to treat a subject having or at risk for a disease or condition described herein. The information can be provided in a variety of formats, including printed text, computer readable material, video recording, or audio recording, or information providing a link or address to substantial material, e.g., on the internet.

[0265] In addition to the antibody, the composition in the kit may include other components such as a solvent or buffer, a stabilizer, or a preservative. The antibody may be provided in any form, e.g., liquid, dry, or lyophilized form, preferably substantially pure and / or sterile. If the agent is provided in a liquid solution, the liquid solution is preferably an aqueous solution. If the agent is provided as a dry form, reconstitution is generally by the addition of a suitable solvent. A solvent, e.g., sterile water or buffer, may optionally be provided in the kit.

[0266] The kit may include one or more containers for one or more compositions containing the agent. In some embodiments, the kit contains separate containers, dividers, or compartments for the composition and the informational material. For example, the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are contained within a single undivided container. For example, the composition is contained in a bottle, vial, or syringe with the informational material attached thereto in the form of a label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms of the agent (e.g., a dosage form described herein). The container can include a combination unit dosage, e.g., a unit containing both an antibody described herein and a second agent, e.g., in a desired ratio. For example, the kit includes a plurality of syringes, ampoules, foil packets, blister packs, or medical devices, e.g., each containing a single combination unit dose. The containers of the kit can be airtight, waterproof (e.g., impermeable to changes in moisture or evaporation), and / or light-tight. The kit optionally includes a device suitable for administration of the compositions, such as a syringe or other suitable delivery device. The device can be provided preloaded with one or both of the agents or can be empty but suitable for loading.

[0267] How to Select the Anti-Integrin Antibody of Interest Some aspects of the disclosure provide methods of selecting, discovering, or isolating an antibody of interest using any of the anti-integrin antibodies described herein. The antibody of interest can be an antibody that binds to αvβ1 integrin but not to other integrins (e.g., other αv or β1 containing integrins or RGD family integrins), an antibody that binds to αvβ1 and αvβ6 integrin but not to other integrins, or an antibody that binds to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3.

[0268] As an example, to select an anti-integrin antibody of interest, a guided selection process can be performed using an induced antibody, which can be an antibody described herein (such as exemplary antibodies 1-10) that binds to αvβ1 integrin but not to other integrins (e.g., other αv or β1-containing integrins, or RGD family integrins). For example, a labeled recombinant or purified αvβ1 integrin (e.g., one or more polypeptides comprising the extracellular domains of αv and β1) and a prokaryotic or eukaryotic (e.g., yeast) antibody expression library can be provided. Clones in the antibody expression library that exhibit reduced binding to the labeled antigen upon addition of the induced antibody can be selected, which are enriched for the antibody of interest. Further description of the guided selection process can be found, for example, in Cherf et al., J. Immunol. 1999, 143:1311-1323, 1999. and Cochran, Methods Mol Biol. 1319:155-75, 2015; Xu et al. Protein Eng Des Sel. 26(10):663-70, 2013; and Mann et al. ACS Chem Biol. 8(3):608-16, 2013. In some cases, any one or more of exemplary antibodies 11-14 and 15-20 can be used as an induced antibody to select, discover, or isolate an antibody of interest (e.g., an antibody that binds to αvβ1 integrin but not to other integrins (e.g., other αv or β1-containing integrins, or RGD family integrins), an antibody that binds to αvβ1 and αvβ6 integrin but not to other integrins, or an antibody that binds to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3).

[0269] To select antibodies that bind to αvβ1 integrin but not to other integrins (e.g., other αv or β1 containing integrins, or RGD family integrins), for example, the method may further comprise depleting antibodies that bind to undesired integrins, e.g., αv or β1 containing integrins, or RGD family integrins (including αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3). The method may also comprise a positive selection step using the target integrin of interest, αvβ1 integrin. Antibodies that bind to αvβ1 and αvβ6 integrin but not to other integrins can be similarly selected by depleting antibodies that bind to integrins other than αvβ1 and αvβ6 and / or by performing positive selection with αvβ1 and αvβ6 integrins. Such principles also apply to the selection of antibodies that bind to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1 and αIIBβ3.

[0270] Antibodies enriched via one or more of the above steps can also be subjected to affinity maturation to increase affinity and specificity for the target integrin and construct libraries using methods known in the art for affinity optimization (e.g., light chain shuffling or H-CDR1 / H-CDR-2 targeted mutagenesis). EXAMPLES

[0271] The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the invention. To the extent that specific materials are mentioned, they are merely for illustration and are not intended to limit the invention. Those skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

[0272] Example 1: Antibody selection and antibody production design Integrin αvβ1 is known to bind to several extracellular matrix proteins. The heterodimeric complex is a combination of the alpha subunit αv and the beta subunit β1 (SEQ ID NOs: 1 and 2). The αv subunit can functionally pair with four additional β subunits: β3, β5, β6, and β8. The β1 subunit can functionally pair with eleven additional α subunits: α1, α2, α3, α4, α5, α6, α7, α8, α9, α10, α11 (Hynes RO, Cell, 110(6):673-87(2002)).

[0273] Integrin αvβ1 was recombinantly expressed and purified according to methods known in the art. Additionally, integrins αvβ3, αvβ5, αvβ6, αvβ8, α4β1, α5β1, and α8β1 were recombinantly expressed and purified according to methods known in the art. The present disclosure describes three different antibody groups: antibodies that bind to αvβ1 integrin but not other integrins (e.g., not other αv or β1 containing integrins), antibodies that bind to αvβ1 and αvβ6 integrin but not other integrins, and antibodies that bind to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3.

[0274] To generate these antibody panels, Adimab expression libraries were screened according to the methods disclosed in US Patent Publication Nos. 2010 / 0056386 and 2009 / 0181855. Multiple iterative rounds of selective pressure towards the antigen of interest αvβ1 (SEQ ID NOs: 1 and 2) and selective pressure to reduce binding to undesirable antigens αvβ3, αvβ5, αvβ6, αvβ8, α4β1, α5β1, and α8β1 were performed. In selections where binding to αvβ1 and αvβ6 was desired, iterative rounds of selective pressure against αvβ6 were introduced and rounds to reduce binding to αvβ6 were eliminated. Selections can also be designed to use a guide protein (i.e., mAb, Fab, or ligand) to guide to the epitope of interest. Selections were performed in the presence and absence of cations including calcium, magnesium, and manganese. After selection was completed, colonies were sequenced to identify unique clones using techniques known in the art. After four campaigns, over 2500 antibodies were expressed and purified on yeast-derived Protein A resin using methods known in the art. A general overview of the triage of αvβ1-specific antibodies, αvβ1 / αvβ6-specific antibodies, and antibodies that bind to αvβ1+1 or more integrins is shown in Figure 1.

[0275] Antibody optimization was also performed to increase the affinity of certain antibodies to αvβ1 as well as fine-tune the integrin specificity. Antibody libraries were constructed using methods known in the art for affinity optimization (i.e., light chain shuffling and H-CDR1 / H-CDR-2 targeted mutagenesis). Multiple iterative rounds of selection pressure against the antigen of interest were applied using decreasing concentrations of αvβ1 recombinant protein. Selection pressure was performed to reduce binding to undesirable antigens αvβ3, αvβ5, αvβ6, αvβ8, α4β1, α5β1, and α8β1. After selection was completed, colonies were sequenced to identify unique clones using techniques known in the art. Following the antibody optimization campaign, over 500 antibodies were expressed and purified on yeast-derived Protein A resin using methods known in the art.

[0276] This analysis identified 20 antibodies, the amino acid sequences of the CDRs and variable regions of which are provided herein.

[0277] Example 2: Determination of binding kinetics and integrin specificity After campaigns 1-3, antibodies were first screened for positive binding to αvβ1 in the presence or absence of cations. Positive antibodies were then screened for binding to other αv- and β1-containing integrins. This screening step was performed to focus future characterization on antibodies that recognize a combination of αv and β1 subunits and to eliminate antibodies that recognize only αv or β1 subunits. This step also allows stratifying antibodies based on their binding preference to RGD-binding integrins (i.e., αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, αIIBβ3) and non-RGD-binding β1-containing integrins (i.e., α4β1).

[0278] Antibodies were screened for binding to the target antigen using Biolayer Interferometry (BLI). BLI was performed on ForteBio Octet RED384 and Octet HTX instruments according to standard procedures. A subset of antibodies was classified based on specificity for subsequent screening in additional assays.

[0279] Examples of observed binding kinetics for αvβ1-specific, non-specific, and partially selective antibodies are shown in Figures 2A-K and 3A-E. Additionally, monovalent binding affinities for recombinant αvβ1 are shown in Figures 4A-J, which include antibodies from the original three campaigns and the subsequent affinity optimization campaign. Monovalent affinity screening after affinity maturation allowed the selection of the highest affinity clones from the optimization for further characterization.

[0280] Examples of antibodies that exhibit specificity for αvβ1 include Exemplary Antibody 1 and Exemplary Antibody 2. Examples of partially selective antibodies include Exemplary Antibody 15 and Exemplary Antibody 16. Higher affinity antibodies selected after affinity maturation include Exemplary Antibody 4 and Exemplary Antibody 5.

[0281] Example 3: Determination of cell surface binding and integrin specificity Stable transfected cells expressing αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α4β1, α5β1, and α8β1 were generated by methods known in the art.

[0282] After campaigns 1-3, antibodies were initially screened by Octet RED384 and Octet HTX. A subset of antibodies was selected for additional specificity screening and affinity measurements on transfected and untransfected cells. After campaign 4, antibodies were screened directly on stably transfected cells expressing αvβ1. Positive antibodies were then screened for binding to other αv- and β1-containing stably transfected cells. This screening step was performed to narrow down the selection to antibodies that recognize combinations of αv and β1 subunits for further characterization and to eliminate antibodies that recognize only αv or β1 subunits. This step also allows stratifying antibodies based on their preference for binding to RGD-binding integrins (i.e., αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, αIIBβ3) and non-RGD-binding β1-containing integrins (i.e., α4β1).

[0283] After an initial cell binding screen at 1-3 concentrations, titrations of 6 or 11 pt were performed against multiple αv-containing and β1-containing cell lines.

[0284] Cells were harvested and confirmed to be >90% viable. Cells were washed three times in the appropriate assay buffer by pelleting at 1500 rpm for 3 min and then pouring off the supernatant. The assay buffer for this experiment was TBS containing 1 mg / mL BSA and supplemented with either 1 mM Ca + 1 mM Mg or 1 mM Mn. Cells were then diluted to 1.0-1.5 x 10 6 Cells were resuspended in assay buffer at a concentration of 100 cells / mL and transferred to wells of a 96-well assay plate (Corning 3799) in 50 μL aliquots. The plate was then centrifuged at 2000 RPM for 3 minutes to pellet the cells and the supernatant was flicked out. Cells were resuspended in 100 μL of antibody sample and incubated on ice for 45-60 minutes. Lower antibody concentrations required longer incubation times.

[0285] The plate was pelleted at 2000RPM for 3 minutes and then washed 3 times in 150μL of assay buffer by flicking out the supernatant. The cells were then resuspended in 50μL of phycoerythrin-conjugated goat anti-human Fab secondary reagent and incubated on ice in the dark for 30 minutes. The plate was pelleted at 2000RPM for 3 minutes and then washed 3 times in 150μL of assay buffer by flicking out the supernatant. The cells were then resuspended in 200μL of assay buffer + 1% polyformaldehyde (PFA) for 30 minutes on ice to fix the cells. The cells were pelleted to remove the PFA and then resuspended in 150μL of assay buffer.

[0286] Cell populations were analyzed on a BD FACSCALIBUR flow cytometer.

[0287] Examples of observed binding titrations of αvβ1-specific and partially selective antibodies are shown in Figures 5A-E and 6A-J, including antibodies from the original four campaigns and the subsequent affinity optimization campaign. Bivalent affinities for cell surface binding (i.e., EC50) are summarized for a subset of RGD-binding integrins in Table 1. [Table 1-1] [Table 1-2]

[0288] Examples of antibodies that exhibit specificity for αvβ1 include Exemplary Antibody 5, Exemplary Antibody 4, Exemplary Antibody 7, and Exemplary Antibody 8. Examples of antibodies that exhibit specificity for both αvβ1 and αvβ6 include Exemplary Antibody 11, Exemplary Antibody 12, and Exemplary Antibody 14. Examples of antibodies that are partially selective (i.e., bind to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIBβ3) include Exemplary Antibody 19 and Exemplary Antibody 17.

[0289] Example 4: αvβ1 latency-related peptide adhesion inhibition After specific and partially selective antibodies were determined, they were tested in the latency-associated peptide (LAP) adhesion assay to confirm their ability to block integrin / ligand interactions in order to narrow down the focus to antibodies that could disrupt functional biological activity. LAP is one of many ligands for the αvβ1 heterodimer, as well as other integrin heterodimers, including αvβ6 and αvβ8.

[0290] 96-well microtiter plates (Costar 3369) were coated overnight at 4°C with 100 μl / well of 10 μg / ml LAP (R&D Systems, Cat. No. 246-LP) diluted in 50 mM sodium bicarbonate (pH 9.2). Plates were washed twice with PBS (200 μl / well), blocked for 1 h at room temperature with 1% BSA in PBS (200 μl / well), and washed three times with 200 μl / well of assay buffer (TBS, 2 mM glucose, 0.1% BSA, 1 mM CaCl2 and 1 mM MgCl2, pH 7.4). Stably transfected human αvβ1 cells were removed from the cell suspension and centrifuged at 1100 rpm for 5 min. The pellet was then washed with RPMI 200 μl / well for 2 h at room temperature. The labeled cells were resuspended in 1% BSA buffer and incubated with 2 μM fluorescent dye (BCECF, Molecular Probes, Eugene, OR) for 30 minutes in a 37° C. incubator. The labeled cells were washed twice by centrifugation at 1100 rpm for 5 minutes and diluted with 0.8×10 6 Cells were resuspended at 2000 ng / ml. 50 μl of purified antibody and 50 μl of BCECF-labeled human αvβ1 cells were added to individual wells of the washed plate and the plate was incubated for 1 h at room temperature in the dark. Plates were washed 3-4 times with assay buffer (200 μl / well) and fluorescence from cells attached on the plate was recorded at 485 nm (excitation) and 538 nm (emission) wavelengths. Percent binding was determined by comparing the fluorescence before the final wash step (i.e., total cells added) to the fluorescence after washing (i.e., cells bound).

[0291] Examples of αvβ1 LAP adhesion inhibition are shown in Figure 7A-E, including a pan-αv commercial antibody (L230), a pan-β1 commercial antibody (mAb13), a published β6 specific antibody, and an example of a c8 small molecule compound previously published as αvβ1 specific (Reed NI et al, Sci Transl Med, 7(288):288ra79(2015)). Inhibition of cell-based adhesion (i.e., IC50) is summarized for all antibodies in Table 2. [Table 2]

[0292] Examples of antibodies that inhibit LAP adhesion include Exemplary Antibody 5, Exemplary Antibody 17, Exemplary Antibody 11, Exemplary Antibody 14, and Exemplary Antibody 8. Examples of antibodies that do not inhibit LAP adhesion include Exemplary Antibody 18.

[0293] Example 5: α4β1 Vascular Cell Adhesion Protein (VCAM) Adhesion Inhibition The specificity of αvβ1 integrin against other RGD-binding integrins was established by Octet screening for recombinant protein and / or cell surface binding to stably transfected cell lines. The antibodies were also tested for binding to α4β1, a β1-containing integrin that does not bind to RGD-containing ligands. To confirm the absence of binding to α4β1 in Example 3, the antibodies were tested in cell adhesion assays to determine whether they inhibit α4β1 / ligand (i.e., VCAM) interactions. It is undesirable to show additional cross-reactivity against β1-containing integrins.

[0294] 96-well microtiter plates (Costar 3369) were coated overnight at 4° C. with 100 μl / well of 10 μg / ml VCAM-Ig diluted in 50 mM sodium bicarbonate (pH 9.2). Plates were washed twice with PBS (200 μl / well), blocked with 1% BSA in PBS (200 μl / well) for 1 h at room temperature, and washed three times with 200 μl / well of assay buffer (TBS, 2 mM glucose, 0.1% BSA, 1 mM CaCl2 and 1 mM MgCl2, pH 7.4). Jurkat cells were removed from the cell suspension and centrifuged at 1500 rpm for 5 min. The pellet was resuspended in RPMI 1640, 1% BSA buffer and incubated with 2 μM fluorescent dye (BCECF, Molecular Probes, Eugene, OR) in a 37° C. incubator for 30 min. The labeled cells were washed twice by centrifugation at 1100 rpm for 5 min and diluted with 0.8X10 6 Cells were resuspended at 2000 ng / ml. 50 μl of purified antibody and 50 μl of BCECF-labeled Jurkat cells were added to individual wells of the washed plate and the plate was incubated for 1 h at room temperature in the dark. The plate was washed 3-4 times with assay buffer (200 μl / well) and the fluorescence from the cells adherent on the plate was recorded at 485 nm (excitation) and 538 nm (emission) wavelengths. Percent binding was determined by comparing the fluorescence before the final wash step (i.e., total cells added) to the fluorescence after the wash (i.e., cells bound).

[0295] Examples of α4β1 VCAM adhesion inhibition are shown in FIG. 8. These include a pan-αv commercial antibody (L230), a pan-β1 commercial antibody (mAb13), a published α4 specific antibody (natalizumab), and an example of a c8 small molecule compound previously published as αvβ1 specific (Reed NI et al, Sci Transl Med, 7(288):288ra79(2015)). This data confirms that the antibodies do not bind to α4β1 or interfere with cell adhesion. Examples include Exemplary Antibody 17, Exemplary Antibody 19, Exemplary Antibody 4, and Exemplary Antibody 5. As expected, mAb13 (pan-β1) and natalizumab (α4) antibodies inhibit adhesion. The c8 small molecule compound does not inhibit α4β1 / VCAM adhesion, although α4β1 binding was not identified in the original publication. Subsequent published studies have highlighted the unknown and potentially undesirable integrin cross-reactivity of c8 small molecule compounds (Wilkinson AL et al, Eur J Pharmacol, 842:239-247(2019)). Results from the α4β1 VCAM adhesion inhibition assay confirm that c8 binds to α4β1 with sufficient affinity to disrupt binding to VCAM.

[0296] Example 6: Fibroblast Binding Assay Binding to αvβ1 on endogenous cell lines (i.e., not genetically engineered) is also desirable. To directly target fibroblasts, antibody binding was tested on MRC9 cells, a human lung fibroblast cell line, and BLO-11, a mouse skeletal muscle fibroblast cell line.

[0297] MRC9 cells were obtained from Sigma (#85020202) and maintained in EMEM (ATCC, #30-2003) supplemented with 10% fetal bovine serum (FBS from Gibco, #16000-077). BLO-11 cells were obtained from ATCC (#CCL-198) and maintained in DMEM (ATCC, #30-2002) supplemented with 10% FBS. Cells were harvested by incubation with cell dissociation buffer (Gibco, #13150-016) for 10 min at 37°C, followed by incubation with CaCl2 and MgCl2 (FACS). ++ The cells were washed with FACS buffer containing PBS + 1% BSA + 1 mM CaCl2 + 1 mM MgCl2). All staining and washing steps were performed with FACS buffer. ++ 0.75×10 per well in 96-well U-bottom plates. 6 Cells were plated and then spun down to remove the supernatant. Cells were then resuspended in serially diluted primary antibodies and incubated for 30 min. After incubation, cells were washed twice and then incubated with α-human IgG Alexa Fluor 647 (Invitrogen, #A21445) secondary antibody for an additional 30 min. Cells were then washed twice and fixed with 1% PFA diluted in PBS for 30 min followed by a final wash. Fluorescence-activated cell sorting (FACS) analysis was performed using a 5-laser BD LSR-II flow cytometer (BD Biosciences, San Jose, CA, USA) and data was analyzed using FlowJo software v9 (Treestar, Ashland, OR, USA) and transferred to analysis and graphics software including GraphPad Prism 7 (La Jolla, CA, USA).

[0298] Examples of observed binding to MRC9 (human fibroblasts) and BLO-11 (mouse fibroblasts) are shown in Figures 9A-D. Examples of antibodies that bind to human and mouse fibroblast cell lines include Exemplary Antibody 17, Exemplary Antibody 5, Exemplary Antibody 19, and Exemplary Antibody 4.

[0299] Example 7: LPA-induced PAI-1 assay To determine whether blocking αvβ1 with antibodies inhibits TGFβ signaling, we performed a cell-based assay using plasminogen activator inhibitor-1 (PAI-1) gene expression levels as a downstream readout of TGFβ receptor signaling.

[0300] MRC9 cells were obtained from ATCC (#CCL-212) and maintained in EMEM (ATCC, #30-2003) supplemented with 10% heat-inactivated fetal bovine serum (FBS, #10082, obtained from Gibco). Cells were seeded in laminin-coated 96-well plates (Corning, #354410) at 40,000 cells per well in complete medium (EMEM supplemented with 10% FBS) and incubated overnight at 37°C with 5% CO2. Cells were washed with EMEM the next day and serum-starved in EMEM medium for 3 hours at 37°C and 5% CO2. Cells were then washed twice with EMEM and incubated in EMEM supplemented with 0.1% bovine serum albumin (BSA, obtained from Millipore, #126626) with or without inhibitors. After 30 min incubation, cells were simulated with 5 μM lysophosphatidic acid (LPA, from Sigma-Aldrich, #L7260) previously dissolved in EMEM + 0.1% BSA. After 20-24 h incubation at 37 °C with 5% CO2, cell culture medium was removed and plates were stored at -80 °C until qPCR analysis. Gene expression levels of PAI-1 (also known as SERPINE1) and GAPDH were assessed using Taqman Cells-to-CT kit (Ambion, #AM1729), Taqman Gene Expression Master (Ambion, #4369016) with human TaqMan probes (SERPINE 1 #4351368 and GAPDH #4448491 from Applied Biosystems), and qPCR run on an Applied Biosystems Viia 7 system with analysis completed on Quantstudio Real-Time PCR Software.

[0301] Examples of PAI-1 inhibition are shown in Figures 10A-C, including examples of a pan-αv commercial antibody (17E6), a pan-β1 commercial antibody (mAb13), and a negative control antibody. Exemplary antibody 17, exemplary antibody 5, and exemplary antibody 19 demonstrate inhibition of TGFβ signaling.

[0302] Example 8: Methods for antibody selection Recombinant secreted human αvβ1 was purified from the supernatant of CHO cells transfected with co-expression of individual α and β subunits by methods known in the art (Weinreb PH, J Biol Chem. 2004 Apr 23;279(17):17875-87; Chen LL, Cell Commun Adhes. 2008 Nov;15(4):317-31; Zhu J, Mol Cell, 2008 Dec 26;32(6),849-61). Three recombinant versions of integrin αvβ1 were used for selection: (1) the complete extracellular domain of αvβ1 without any additional tags, (2) the complete extracellular domain of αvβ1 and β1 fused to the hinge+Fc portion of hIgG1+Avitag (αvβ1-Fc), and (3) the complete extracellular domain of αvβ1 in which the αv subunit was fused to a TEV-acidic coiled-coil-StrepII tag and the β1 subunit was fused to TEV-basic coiled-coil-6xHIS-G4S-Avitag (αvβ1-cc-AVI) (see Weinreb et al. J. Biol. Chem. 279(17):17875-17887, 2004; Chen et al. Cell Communication and Adhesions, 15:317-331, 2008; and Zhu et al. Molecular Cell 32:849-861, 2008). In addition, recombinant secreted human αvβ3, αvβ5, αvβ6, αvβ8, α4β1, α5β1, and α8β1 were produced by a similar method as recombinant version #3 (with coiled-coil tag). All recombinant integrin proteins were biotinylated for selection.

[0303] Selections were performed with the Adimab yeast expression library using purified and biotinylated recombinant αvβ1 versions 1, 2, and 3. Selections were performed in cation-free buffer, and in buffer containing CaMg, or buffer containing Mn. The first two rounds of selection were performed using magnetic activated cell sorting (MACS), and all subsequent rounds were performed using fluorescence activated cell sorting (FACS). The use of a FACS-based platform allows visualization of the selection of antibody libraries displayed in yeast or other cells (prokaryotic or eukaryotic). This visualization allows selections to be designed to direct the antibody library to the epitope of interest using a guide protein (e.g., mAb, Fab, ligand, or depletion protein) (see, e.g., Cherf and Cochran, Methods Mol Biol. 1319:155-75, 2015; Xu et al., 2013). (see, for example, E. et al. Protein Eng Des Sel. 26(10):663-70, 2013, and Mann et al. ACS Chem Biol. 8(3):608-16, 2013). If robust enrichment was observed after round 3, subsequent rounds were directed to the epitope of interest using L230 (a pan-αv commercial antibody) and / or depletion on αv-containing integrins (αvβ3 or αvβ5) and β1-containing integrins (α5β1 or α4β1). Using these conditions, the output could be narrowed down to antibodies that bind to multiple RGD-binding integrins, and antibodies specific for αvβ1. Depending on the stringency of the depletion, the selection identified αvβ1-specific antibodies (e.g., exemplary antibodies 1, 2, 3) or antibodies that bind to multiple RGD-binding integrins (e.g., exemplary antibodies 15, 16). Subsequent antibody optimization was performed to increase the affinity of certain antibodies to αvβ1 as well as fine-tune the integrin specificity. Antibody libraries were constructed using methods known in the art for affinity optimization (i.e., light chain shuffling and H-CDR1 / H-CDR-2 targeted mutagenesis). After affinity maturation, the antibodies were either specific for αvβ1 integrin (e.g., exemplary antibodies 4 and 5) or bound to multiple RGD-binding integrins (e.g., exemplary antibodies 17, 18, 19).

[0304] After isolating αvβ1 specific antibodies, future guided selections can be performed using these antibodies. A new selection was performed with the Adimab yeast expression library using purified and biotinylated recombinant αvβ1 version 3. Selection was performed in buffer containing CaMg. The first two rounds of selection were performed using MACS, and all subsequent rounds were performed using FACS. Robust enrichment was observed after the third round, and exemplary antibody 5 was used to guide in the fourth round to a more refined epitope than that achieved in the previous selection using L230. Subsequent depletion rounds were performed against αv-containing integrins (αvβ3, αvβ5, or αvβ6) and / or β1-containing integrins (α5β1 or α8β1), in some cases followed by a positive αvβ1 selection round. The output from these selections also underwent affinity maturation to increase affinity and specificity for αvβ1 or αvβ1 / αvβ6, and libraries were constructed using methods known in the art for affinity optimization (i.e., light chain shuffling and H-CDR1 / H-CDR-2 targeted mutagenesis). After enrichment for αvβ1, depletion rounds were performed with αvβ8 and α5β1 or α8β1, in some cases followed by a positive αvβ1 selection round. Depending on the stringency of depletion, affinity optimization selections identified αvβ1-specific antibodies (i.e., exemplary antibodies 6, 7, 8, 9, 10), αvβ1 / αvβ6-specific antibodies (i.e., exemplary antibodies 11, 12, 13, 14), or antibodies that bind to multiple RGD-binding integrins (i.e., exemplary antibody 20).

[0305] Sequences referenced in this example: The amino acid sequence of human integrin αv protein in recombinant integrin αvβ1 version #1 is shown below. (SEQ ID NO:117)

[0306] The amino acid sequence of human integrin β1 protein in recombinant integrin αvβ1 version #1 is shown below. (SEQ ID NO:118)

[0307] The amino acid sequence of human integrin αv protein in recombinant integrin αvβ1 version #2 is shown below. (SEQ ID NO:117)

[0308] The amino acid sequence of human integrin β1 protein in recombinant integrin αvβ1 version #2 is shown below, where the underlined sequence indicates the sequence including the hinge, hIgG1 Fc region, and Avitag. [ka]

[0309] The amino acid sequence of human integrin αv protein in recombinant integrin αvβ1 version #3 is shown below, with the underline indicating the TEV-acidic coiled-coil-StrepII tag. [ka]

[0310] The amino acid sequence of human integrin β1 protein in recombinant integrin αvβ1 version #3 is shown below, with the underline indicating TEV basic coiled-coil-6xHIS-Avitag. [ka]

[0311] Other embodiments While the present invention has been described in conjunction with its detailed description, the foregoing description is intended to be illustrative, and not limiting, of the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. The present invention provides, for example, the following items. (Item 1) An antibody that specifically binds to αvβ1 integrin but not to other integrins, optionally having one or more of the following properties: (i) binding to human αvβ1 with high affinity (bivalent affinity) with a KD of ≦20 nM, (ii) blocking αvβ1 interaction with its ligand, (iii) being cation-dependent with respect to binding to human αvβ1, (iv) being cation-independent with respect to binding to human αvβ1, (v) binding to αvβ1 on fibroblasts, and (vi) inhibiting fibroblast TGFβ response. (Item 2) The antibody competes with and / or binds to the same epitope as a reference anti-αvβ1 integrin antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the VH and VL of the reference antibody being (i) the amino acid sequence shown in SEQ ID NO: 35 and the amino acid sequence shown in SEQ ID NO: 22, respectively; (ii) the amino acid sequence shown in SEQ ID NO: 61 and the amino acid sequence shown in SEQ ID NO: 58, respectively; (iii) the amino acid sequence shown in SEQ ID NO: 11 and the amino acid sequence shown in SEQ ID NO: 12, respectively; (iv) the amino acid sequence shown in SEQ ID NO: 21 and the amino acid sequence shown in SEQ ID NO: 22, respectively; (v) the amino acid sequence shown in SEQ ID NO: 27 and the amino acid sequence shown in SEQ ID NO: 28, respectively; (vi) the amino acid sequence shown in SEQ ID NO: 30 and the amino acid sequence shown in SEQ ID NO: 12, respectively; (vii) the amino acid sequence shown in SEQ ID NO: 44 and the amino acid sequence shown in SEQ ID NO: 45, respectively; (viii) the amino acid sequence shown in SEQ ID NO: 49 and the amino acid sequence shown in SEQ ID NO: 50, respectively; (ix) the amino acid sequence shown in SEQ ID NO: 57 and the amino acid sequence shown in SEQ ID NO: 58, respectively; or (x) The antibody according to item 1, comprising the amino acid sequence shown in SEQ ID NO: 64 and the amino acid sequence shown in SEQ ID NO: 58, respectively. (Item 3) An antibody that specifically binds to both αvβ1 and αvβ6 integrins but not to other integrins, optionally having one or more of the following properties: (i) binding to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to human αvβ6 with affinity (bivalent affinity) of 100 nM, (ii) blocking αvβ1 and / or αvβ6 interaction with its ligand, (iii) being cation-dependent with respect to binding to human αvβ1 and / or αvβ6, (iv) binding to αvβ1 on fibroblasts, and (v) inhibiting fibroblast TGFβ response. (Item 4) The antibody binds to both αvβ1 and αvβ6 integrins and competes with and / or binds to the same epitope as a reference antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL of the reference antibody are (i) the amino acid sequence shown in SEQ ID NO: 44 and the amino acid sequence shown in SEQ ID NO: 68, respectively; (ii) the amino acid sequence shown in SEQ ID NO: 44 and the amino acid sequence shown in SEQ ID NO: 70, respectively; (iii) the amino acid sequence set forth in SEQ ID NO: 49 and the amino acid sequence set forth in SEQ ID NO: 72, respectively; or (iv) The antibody according to item 3, comprising the amino acid sequence shown in SEQ ID NO: 76 and the amino acid sequence shown in SEQ ID NO: 77, respectively. (Item 5) An antibody that specifically binds to αvβ1 and one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1 and αIIBβ3, optionally having one or more of the following properties: (i) binding to human αvβ1 with high affinity (bivalent affinity) of KD≦20 nM and to other RGD-binding integrins with an affinity (bivalent affinity) of 100 nM; (ii) blocking αvβ1 and / or RGD family integrin interactions with its ligands; (iii) being cation-dependent with respect to binding to human αvβ1 and / or RGD-binding integrins; (iv) being cation-independent with respect to binding to human αvβ1 and / or RGD-binding integrins; (v) binding to αvβ1 and / or RGD-binding integrins on fibroblasts; and (vi) inhibiting fibroblast TGFβ response. (Item 6) The antibody competes with and / or binds to the same epitope as a reference antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the VH and VL of the reference antibody being (i) the amino acid sequence shown in SEQ ID NO: 82 and the amino acid sequence shown in SEQ ID NO: 83, respectively; (ii) the amino acid sequence shown in SEQ ID NO: 92 and the amino acid sequence shown in SEQ ID NO: 93, respectively; (iii) the amino acid sequence shown in SEQ ID NO: 92 and the amino acid sequence shown in SEQ ID NO: 95, respectively; (iv) the amino acid sequence shown in SEQ ID NO: 100 and the amino acid sequence shown in SEQ ID NO: 28, respectively; (v) the amino acid sequence set forth in SEQ ID NO: 21 and the amino acid sequence set forth in SEQ ID NO: 104, respectively; or (vi) The antibody according to item 5, comprising the amino acid sequence shown in SEQ ID NO: 49 and the amino acid sequence shown in SEQ ID NO: 107, respectively. (Item 7) An antibody that binds to αvβ1 integrin but not to other integrins, comprising a VH comprising VHCDR1, VHCDR2 and VHCDR3, and a VL comprising VLCDR1, VLCDR2 and VLCDR3, wherein the VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 are (i) SEQ ID NOs: 32, 34, 17, 18, 19, and 20, respectively; (ii) SEQ ID NOs: 60, 39, 55, 18, 19, and 56, respectively; (iii) SEQ ID NOs: 4, 6, 7, 8, 9, and 10, respectively; (iv) SEQ ID NOs: 14, 16, 17, 18, 19, and 20, respectively; (v) SEQ ID NOs: 4, 6, 23, 24, 25, and 26, respectively; (vi) SEQ ID NOs: 29, 6, 7, 8, 9, and 10, respectively; (vii) SEQ ID NOs: 37, 39, 40, 41, 42, and 43, respectively; (viii) SEQ ID NOs: 37, 39, 46, 18, 47, and 48, respectively; (ix) SEQ ID NOs: 52, 54, 55, 18, 19, and 56, respectively; or (x) The antibody comprising sequence numbers 63, 54, 55, 18, 19, and 56, respectively. (Item 8) (i) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 35 and 22, respectively; (ii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 61 and 58, respectively; (iii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; (iv) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 21 and 22, respectively; (v) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 27 and 28, respectively; (vi) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 30 and 12, respectively; (vii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 44 and 45, respectively; (viii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 49 and 50, respectively; (ix) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 57 and 58, respectively; or (x) The antibody of item 7, wherein the VH and VL comprise amino acid sequences that are at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 64 and 58, respectively. (Item 9) An antibody that binds to both αvβ1 and αvβ6 integrins but does not bind to other integrins, comprising a VH comprising VHCDR1, VHCDR2 and VHCDR3, and a VL comprising VLCDR1, VLCDR2 and VLCDR3, wherein the VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 are (i) SEQ ID NOs: 37, 39, 40, 65, 66, and 67, respectively; (ii) SEQ ID NOs: 37, 39, 40, 65, 66, and 69, respectively; (iii) SEQ ID NOs: 37, 39, 46, 18, 47, and 71, respectively; or (iv) The antibody comprises SEQ ID NO: 37, 39, 73, 74, 42, and 75, respectively. (Item 10) (i) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 44 and 68, respectively; (ii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 44 and 70, respectively; (iii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 49 and 72, respectively; or (iv) The antibody of item 9, wherein the VH and VL comprise amino acid sequences that are at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 76 and 77, respectively. (Item 11) An antibody that binds to one or more integrins selected from the group consisting of αvβ1 and αvβ6, αvβ3, αvβ5, αvβ8, α5β1, α8β1, and αIIBβ3, comprising a VH comprising VHCDR1, VHCDR2, and VHCDR3, and a VL comprising VLCDR1, VLCDR2, and VLCDR3, wherein the VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 are (i) SEQ ID NOs: 4, 6, 78, 79, 80, and 81, respectively; (ii) SEQ ID NOs: 85, 87, 88, 89, 90, and 91, respectively; (iii) SEQ ID NOs: 85, 87, 88, 89, 90, and 94, respectively; (iv) SEQ ID NOs: 97, 99, 23, 24, 25, and 26, respectively; (v) SEQ ID NOs: 14, 16, 17, 101, 102, and 103, respectively; or (vi) The antibody comprises SEQ ID NO: 37, 39, 46, 105, 80, and 106, respectively. (Item 12) (i) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 82 and 83, respectively; (ii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 92 and 93, respectively; (iii) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 92 and 95, respectively; (iv) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 100 and 28, respectively; (v) the VH and the VL comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NOs: 21 and 104, respectively; or (vi) The antibody of item 11, wherein the VH and VL comprise amino acid sequences that are at least 75%, 80%, 85%, 90%, 95%, or 100% identical to the amino acid sequences set forth in SEQ ID NOs: 49 and 107, respectively. (Item 13) 13. The antibody according to any one of items 1 to 12, wherein the antibody comprises a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region. (Item 14) 13. The antibody according to any one of items 1 to 12, wherein the antibody comprises a non-glycosylated human constant region. (Item 15) 13. The antibody according to any one of items 1 to 12, wherein the antibody comprises hIgG1agly Fc, hIgG2 SAA Fc, hIgG4(S228P) Fc, or hIgG4(S228P) / G1 agly Fc. (Item 16) 16. The antibody according to any one of items 1 to 15, wherein the antibody comprises a human kappa or human lambda light chain constant region. (Item 17) 13. The antibody according to any one of items 1 to 12, wherein the antibody is a whole antibody, a single domain antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an Fv, an scFv, an sc(Fv)2, a diabody, a nanobody, an Fab, or an F(ab')2. (Item 18) 18. The antibody of any one of items 1 to 17, further comprising a half-life extending moiety. (Item 19) 19. The antibody of any one of items 1 to 18, further comprising a detectable label. (Item 20) 20. The antibody of any one of items 1 to 19, further comprising a therapeutic agent. (Item 21) 18. The antibody of any one of items 1 to 17, further comprising a radioisotope. (Item 22) 18. The antibody according to any one of items 1 to 17, further comprising a chemotherapeutic agent or a radiotherapeutic agent. (Item 23) A pharmaceutical composition comprising the antibody according to any one of items 1 to 22. (Item 24) 18. One or more polynucleotides encoding the antibody according to any one of items 1 to 17. (Item 25) 25. One or more vectors comprising one or more polynucleotides according to item 24. (Item 26) A host cell comprising one or more polynucleotides according to item 24 or one or more vectors according to item 25. (Item 27) 1. A method for producing an anti-integrin antibody, comprising: (a) culturing the host cell according to item 26 under conditions allowing expression of the antibody; (b) isolating the antibody. (Item 28) 28. The method of claim 27, further comprising formulating the antibody as a sterile formulation suitable for administration to humans. (Item 29) 21. A method for treating or preventing fibrosis in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 20. (Item 30) 30. The method of claim 29, wherein the fibrosis is selected from the group consisting of hepatic fibrosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, arthrofibrosis, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, Peyronie's disease, progressive massive fibrosis, small airway fibrosis, fibrosis associated with chronic obstructive pulmonary disease, and retroperitoneal fibrosis. (Item 31) 31. The method of claim 30, wherein the fibrosis is liver fibrosis. (Item 32) 30. The method of claim 29, wherein the fibrosis is idiopathic pulmonary fibrosis. (Item 33) 30. The method of claim 29, wherein the fibrosis is scleroderma / systemic sclerosis. (Item 34) 21. A method for treating or preventing chronic kidney disease in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 20. (Item 35) 23. A method for treating or preventing cancer in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 22. (Item 36) 36. The method of claim 35, wherein the cancer is of epithelial origin, and optionally the cancer of epithelial origin is squamous cell carcinoma, adenocarcinoma, transitional cell carcinoma, or basal cell carcinoma. (Item 37) 36. The method of claim 35, wherein the cancer is selected from the group consisting of pancreatic cancer, breast cancer, melanoma, prostate cancer, ovarian cancer, cervical cancer, brain and central nervous system tumors, and glioblastoma. (Item 38) 21. A method for inhibiting platelet aggregation in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 20. (Item 39) 39. The method of claim 38, wherein the inhibition is for the treatment of acute coronary syndrome. (Item 40) 21. A method for treating or preventing an ophthalmic disease or disorder in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 20. (Item 41) 41. The method of claim 40, wherein the ophthalmic disease or disorder is selected from the group consisting of age-related macular degeneration (AMD), wet AMD, macular edema, and diabetic retinopathy. (Item 42) 21. A method for treating or preventing acute kidney injury, acute lung injury, or acute liver injury in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 20. (Item 43) 21. A method for treating or preventing non-alcoholic fatty liver disease (NAFLD) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the antibody according to any one of items 1 to 20. (Item 44) Item 44. The method of item 43, wherein the NAFLD is nonalcoholic steatohepatitis (NASH). (Item 45) 13. A method for identifying an antibody that specifically binds to αvβ1 integrin but not to other integrins from a population of antibodies, the method comprising selecting said antibody using guided selection with an induced antibody, the induced antibody being any one of the antibodies according to items 1, 2, 4, or 6-12. (Item 46) 46. ​​The method of claim 45, wherein the antibody population comprises an antibody library expressed on the surface of a prokaryotic cell. (Item 47) 46. ​​The method of claim 45, wherein the antibody population comprises an antibody library expressed on the surface of a eukaryotic cell. (Item 48) 46. ​​The method of claim 45, wherein the antibody population comprises an antibody library expressed on the surface of yeast cells. (Item 49) 49. The method according to any one of items 45 to 48, comprising a step of selecting antibodies that bind to one or more polypeptides comprising the extracellular domains of αv and β1, optionally wherein said step is carried out in the absence of cations, in the presence of calcium and magnesium, or in the presence of manganese, and optionally wherein said selection is carried out by MACS and / or FACS. (Item 50) 50. The method of any one of items 45 to 49, further comprising depleting antibodies that bind to one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and α4β1. (Item 51) 51. The method according to any one of items 45 to 50, further comprising enriching for antibodies that specifically bind to αvβ1 integrin by selecting antibodies that bind to αvβ1 integrin. (Item 52) 52. The method according to any one of items 45 to 51, further comprising affinity maturing the selected antibody. (Item 53) 13. A method for identifying an antibody from a population of antibodies, wherein the antibody specifically binds to both αvβ1 and αvβ6 integrin, the method comprising selecting the antibody using guided selection with an induced antibody, the induced antibody being any one of the antibodies according to items 1, 2, 4, or 6-12. (Item 54) 54. The method of claim 53, wherein the antibody population comprises an antibody library expressed on the surface of a prokaryotic cell. (Item 55) 54. The method of claim 53, wherein the antibody population comprises an antibody library expressed on the surface of a eukaryotic cell. (Item 56) 54. The method of claim 53, wherein the antibody population comprises an antibody library expressed on the surface of yeast cells. (Item 57) 57. The method of any one of items 53 to 56, comprising a step of selecting antibodies that bind to one or more polypeptides comprising the extracellular domains of αv and β1, and / or the extracellular domains of αv and β6, optionally wherein said step is performed in the absence of cations, in the presence of calcium and magnesium, or in the presence of manganese, and optionally wherein said selection is performed by MACS and / or FACS. (Item 58) 58. The method of any one of items 53 to 57, further comprising depleting antibodies that bind to one or more integrins selected from the group consisting of αvβ3, αvβ5, αvβ8, α5β1, α8β1, and α4β1. (Item 59) 59. The method according to any one of items 53 to 58, further comprising enriching for antibodies that specifically bind to αvβ1 and αvβ6 integrin by selecting antibodies that bind to αvβ1 and αvβ6 integrin. (Item 60) 60. The method of any one of items 53 to 59, further comprising affinity maturing the selected antibody.

Claims

[Claim 1] The invention described in the specification.